| Excerpt | Reference |
|---|
| "Twenty patients with chronic renal failure and either urinary or respiratory tract infection were treated with co-trimoxazole." | ( de Wardener, HE; MacGregor, GA; Tasker, PR, 1975) |
| "It is suggested that chronic renal failure should be regarded as a contraindication to the use of clofibrate for the treatment of any coexisting hyperlipidaemia." | ( Alvarez-Ude, F; Kerr, DN; Pierides, AM, 1975) |
| "Twelve children with chronic renal failure (CRF) and sixteen children receiving regular dialysis therapy (RDT) were treated with between 10,000 and 50,000 IU of vitamin D daily." | ( Benz, G; Bulla, M; Delling, G; Lühmann, H; Offermann, G; Sanchez de Reutter, A; Severin, M; Ziegler, R, 1979) |
| "Twelve of 56 patients with chronic renal failure, all treated with frusemide (Lasix) in daily doses of 0." | ( Heydenreich, G; Pindborg, T; Schmidt, H, 1977) |
| "In patients with conservatively treated chronic renal failure and those who had received renal transplants, however, there was poor aggrement between the methods." | ( Conceicao, SC; Kerr, DN; Luno, J; Smith, PA; Ward, MK; Weightman, D, 1978) |
| "We present 3 patients with chronic renal failure who had postoperative paralysis due to the administration muscle relaxants." | ( Lewis, EJ; Sirotzky, L, 1978) |
| "Bone marrow smears from 20 patients with chronic renal failure and on regular haemodialysis treatment (RDT) were morphologically analysed." | ( Lindholm, T; Sjögren, U; Thysell, H, 1979) |
| "A patient with mild chronic renal failure developed significant hyperkalaemia while receiving indomethacin therapy." | ( Frost, GW; MacCarthy, EP; Strokes, GS, 1979) |
| "In 14 nondialyzed patients with chronic renal failure (CRF) and at the start of treatment a glomerular filtration rate (GFR) of 14--47 ml/min changes in bone mineral mass (BMM), expressed in percentage of the initial value, showed a significant correlation with the mean GFR during an observation period of 16 +/- 2 mo." | ( Birkenhäger, JC; Hagenouw-Taal, JC; Juttmann, JR; Lameyer, LD; Ruis, AM, 1979) |
| "Between 1972 and 1976 15 patients with chronic renal failure of different aetiology and varying severity were observed who developed 23 hypercalcaemic phases during treatment with calcium-containing drugs." | ( Anlauf, M; Bock, KD; Cremer, W; Graben, N, 1977) |
| "In patients with chronic renal failure the administration of a diet providing 20 g protein per day for five weeks caused a significant rise in the serum ceruloplasmin level." | ( Doberský, P; Heyrovský, I; Marecek, Z; Nádvorníková, H; Pechar, J; Schück, O; Skála, I; Vulterinová, M, 1978) |
| "Six patients with chronic renal failure on regular dialysis treatment were given low doses (0." | ( Kokot, F; Kuska, J; Pietrek, J, 1978) |
| "Seven ESRD patients were treated by hemofiltration (HF) for 3--4 months using an experimental HF machine and RP6 filters (Hospal)." | ( Joliat, A; Leski, M, 1978) |
| "The etiology of anemia associated with chronic renal failure, and the advantages and disadvantages of its treatment with androgenic agents, are reviewed." | ( Alexander, MR, 1976) |
| "Thirtheen male patients with chronic renal failure undergoing regular dialysis treatment (2 X 8-10 hours/week) were treated with gonadotropins (HCG, Primogonyl) primarily 2 X 2,000 IU/week and later 2,000 IU/week." | ( Bundschu, HD; Hayduk, K; Heller, S; Liebau, G; Lüders, G; Pfeiffer, EH; Rager, K, 1976) |
| "In untreated patients with chronic renal failure and glomerular filtration rates (GFR) between 10 and 25 ml/min the decrease in fractional tubular reabsorption of phosphate was correlated to the degree of secondary hyperparathyroidism." | ( Brochner-Mortensen, J; Christensen, MS; Rodbro, P; Sorensen, E; Tougaard, L, 1977) |
| "In 77 patients with chronic renal failure - all were conservative treated - exercise-tests were performed with the bicycle and in 67 cases spiro-ergometric tests." | ( Huber, W; Kempmann, G; Neuss, H; Schaumann, HJ; Scheuerlen, H; Stegaru, B, 1977) |
| "Five adult patients with chronic renal failure and associated renal osteodystrophy have been treated for 6 months with 1-alpha-hydroxycholecalciferol (1 alpha-OH-D3), a synthetic vitamin D analogue." | ( Madsen, S; Olgaard, K, 1976) |
| "In two patients with chronic renal failure, extensive renal osteodystrophy, and vascular calcifications, treatment with high doses of vitamin D3 and aluminum hydroxide was followed by healing of the osteodystrophy and marked resolution of the vascular calcifications." | ( Bouillon, R; Krempien, B; Verberckmoes, R, 1975) |
| "Three patients with chronic renal failure on maintenance haemodialysis have been treated with 1 alpha-hydroxycholecalciferol (1 alpha-OHCC), a synthetic vitamin D analogue." | ( Catto, GR; Kodicek, E; MacLeod, M; Pelc, B, 1975) |
| "When serum from patients with chronic renal failure on maintenance digoxin therapy was analysed, important discrepancies in the results obtained with the 6 kits were found in some of these patients." | ( Belpaire, CM; Bogaert, MG; De Broe, ME, 1975) |
| "In patients with chronic renal failure, NaHCO3 therapy may correct or prevent acidemia." | ( Husted, FC; Maher, JF; Nolph, KD, 1975) |
| "Twenty-nine patients with chronic renal failure on maintenance haemodialysis were accidently exposed to dialysate aluminium levels of 65 micrograms/L (recommended Food and Drug Administration values less than 10 micrograms/L) for 18 months." | ( Amoedo, ML; Fernández, E; Montoliu, J, 1992) |
| "This was unrelated to length of chronic renal failure and number of treatments with ototoxic drugs." | ( Morton, LP; Rayner, BL; Reynolds, L; Zent, R, 1992) |
| "Using a mouse model of chronic renal failure (CRF), the possibility of using lovastatin to treat hypercholesterolemia associated with CRF was examined." | ( Gagnon, RF; Stewart-Phillips, JL; Subang, MC, 1992) |
| "We treated an infant with anemia and chronic renal failure with recombinant human erythropoietin (300 to 750 U/kg subcutaneously per week) and iron (6 mg/kg enterally) from 1 to 4 months of age." | ( DeAlarcon, PA; Guillery, EN; Kling, PJ; Peters, C; Veng-Pedersen, P; Widness, JA, 1992) |
| "Ten patients with chronic renal failure (CRF) treated by hemodialysis (HD) were examined." | ( Balashova, TS; Ermolenko, VM; Kubatiev, AA; Rud'ko, IA; Tsalenchuk, IaP, 1992) |
| "NK activity of the ESRD patients was comparable with that of normal controls at the start of the study and was unaffected by rHuEpo therapy." | ( Levy, S; Mann, RA; Nunn, C; Palekar, S; Singh, AB; Singh, M, 1992) |
| "45 patients with chronic renal failure (25 dialysed and 20 undialysed) were examined for function of vestibular organ and 35 patients with chronic renal failure treated by diet and drugs were examined for hearing acuity by pure tone audiometry and above-threshold audiometry." | ( Kokot, F; Kuska, J; Wróbel, M, 1992) |
| "Twelve patients with chronic renal failure (CRF) requiring dialysis, 7 of whom were hypercalcaemic, were treated with 24,25-dihydroxycholecalciferol [24,25(OH)2D3; 10 micrograms daily for 3 months] or placebo and the treatment then crossed over for a further 3 months." | ( Farrington, K; Moorhead, JF; Varghese, Z, 1992) |
| "As the anemia that accompanies chronic renal failure (CRF) is successfully treated with recombinant human erythropoietin (epoetin), striking improvements in overall quality of life have been noted in several clinical studies of patients receiving chronic hemodialysis." | ( Levin, NW, 1992) |
| "Patients with end-stage renal disease (ESRD) on chronic hemodialysis treatment usually present a deficiency of this active form of vitamin D3." | ( Hübel, E; Kiefer, T; Kuhlmann, U; Mettang, T; Weber, J, 1991) |
| "In patients with chronic renal failure (crf) on conservative treatment whole blood granulocyte superoxide anion (O2-) generation was significantly decreased." | ( Błaszczyk, J; Kedziora, J; Luciak, M; Pawlicki, L; Sibińska, E; Trznadel, K, 1991) |
| "We conclude that patients with chronic renal failure receiving hemodialysis treatment regularly have increased concentrations of eight of nine measured gastrointestinal regulatory peptides." | ( Ekman, R; Hegbrant, J; Thysell, H, 1991) |
| "Four young males with chronic renal failure and absent or stagnant puberty were treated with testosterone esters." | ( Donckerwolcke, RA; Van Steenbergen, MW; Wit, JM, 1991) |
| "Fourteen patients with chronic renal failure and secondary hyperparathyroidism were treated by subtotal parathyroidectomy." | ( Altieri, P; Bolasco, P; Massidda, B; Massidda, C; Nicolosi, A; Tarquini, A, 1991) |
| "Overall 14 patients with chronic renal failure treated by hemodialysis were examined." | ( Kubatiev, AA; Rud'ko, IA; Stel'makov, BG; Tsalenchuk, IaP, 1991) |
| "33 cases of chronic renal failure (CRF) patients were treated by coloclysis with Chinese medicine Shenshuaifang (SSF)." | ( Song, C; Wang, DJ; Zhao, S, 1991) |
| "Twenty-four patients with chronic renal failure, stabilized on hemodialysis, were treated with recombinant human erythropoietin." | ( Brown, WS; Carr, CR; Harper, R; Marsh, JT; Nissenson, AR; Schweitzer, SV; Wolcott, D, 1991) |
| "In experimental chronic renal failure, the long-term administration of verapamil protects against renal dysfunction and damage, independent of any effect on systemic mean arterial pressure." | ( Schrier, RW, 1991) |
| "Thus, both chronic renal failure and a routine hemodialysis treatment produce changes in cell and plasma taurine levels that tend to be specific for the individual cell type." | ( Jung, BC; Kopple, JD; Laidlaw, SA, 1991) |
| "Two groups of patients with chronic renal failure (creatinine clearance 13 ml/min) were treated with two different low protein diets: unselected protein diet with 0." | ( Djukanović, L; Vujić, D, 1990) |
| "We describe a patient with chronic renal failure and transitional cell carcinoma, in whom a nephrogenic adenoma of the bladder was diagnosed after a course of intravesical thiotepa treatment." | ( Embon, OM; Gold, CH; Sazbon, A; Turani, H, 1990) |
| "The anemia of chronic renal failure can now be effectively treated with recombinant human erythropoietin when given in adequate doses." | ( Adamson, JW; Eschbach, JW, 1990) |
| "Under pathological conditions such as chronic renal failure, extrarenal sources have the potential to normalize serum calcitriol after adequate stimulation (such as, 25(OH)D administration)." | ( Brown, A; Delmez, J; Dusso, A; Finch, J; Lopez-Hilker, S; Rapp, N; Slatopolsky, E, 1990) |
| "Eleven patients with predialysis chronic renal failure participated in a double-blind, placebo-controlled study of subcutaneously administered erythropoietin." | ( Cotton, S; Gimenez, LF; Spivak, JL; Walser, M; Watson, AJ, 1990) |
| "Patients with a stable progression of chronic renal failure with a creatinine clearance of 15-45 mL/min were randomly assigned to two groups of antihypertensive therapy: 1--nisoldipine as the only antihypertensive agent and 2--antihypertensive drugs without calcium channel blockers and a placebo tablet instead of nisoldipine." | ( Blau, A; Eliahou, HE; Herzog, D; Sachs, D; Shechter, P, 1990) |
| "Five women aged 50-64 years with chronic renal failure caused by interstitial nephritis, maintained by chronic haemodialysis, were treated for three months with human recombinant erythropoietin." | ( Bartûsková, J; Kasl, M; Kozlová, J; Kvasnicka, J; Podrouzek, P; Sulková, S; Válek, A, 1990) |
| "The majority of patients treated for chronic renal failure die of cardiovascular complications." | ( Antignani, A; Avram, MM; Fein, PA; Goldwasser, P; Lapuz, MH; Lustig, AR; Mittman, N; Mushnick, RA, 1989) |
| "Three groups of patients with acute or chronic renal failure (GFR less than 5 ml/min) and hyperkalaemia (K+ greater than or equal to 6 mEq/l), similar in age, serum creatinine and pretreatment K+." | ( Campistol, JM; Cases, A; Lens, XM; Montoliu, J; Revert, L, 1989) |
| "Seven anaemic patients with predialysis chronic renal failure were treated with human recombinant erythropoietin." | ( Fujishima, M; Kumagai, H; Onoyama, K; Shimamatsu, K; Takeda, K, 1989) |
| "A 61-year-old female patient with ESRD due to analgesic nephropathy and treated solely with CAPD for 81 months is described." | ( Colombi, A; Wegmann, W, 1989) |
| "Ten patients with chronic renal failure whose hypertension was controlled with triple drug therapy consisting of propranolol-hydralazine-furosemide were switched to the angiotensin-converting enzyme (ACE) inhibitor captopril for a period of 12 months." | ( Miranda, B; Morales, JM; Raij, L; Rodicio, JL; Romero, JC; Ruilope, LM, 1989) |
| "Patients with chronic renal failure are also exposed to aluminum in domestic tap-water supplies used either for drinking or, in those on dialysis treatment, in the preparation of their dialysate." | ( Savory, J; Wills, MR, 1989) |
| "The effects of 21 days of chronic renal failure (CRF) with and without excess parathyroid hormone (PTH) and those of 21 days administration of intact PTH on phospholipids and cholesterol contents of rat brain synaptosomes were examined." | ( Islam, A; Massry, SG; Smogorzewski, M, 1989) |
| "When patients with anemia of chronic renal failure were treated with rhEpo at dosages between 40 and 120 U/kg three times per week, the numbers of circulating erythroid burst-forming units (BFU-E) and granulocyte-erythrocyte-macrophage-megakaryocyte colony-forming units (CFU-GEMM) significantly increased during the first week of therapy." | ( Bergmann, M; Ganser, A; Grützmacher, P; Hoelzer, D; Scigalla, P; Völkers, B, 1989) |
| "A 55-year-old woman with chronic renal failure treated with hemodialysis had severe bilateral visual loss develop due to retinal ischemia." | ( Bunt-Milam, AH; Johnson, RJ; Kalina, RE; Qingli, L; Wells, CG, 1989) |
| "10 patients with chronic renal failure (6 women, 4 men), 19 to 59 years of age, duration of the disease form 3 up to 21 years, treated by hemodialysis from 2 to 5 years, were examined." | ( Garcheva, M; Ionova, D; Kiriakov, Z; Simeonova, A, 1988) |
| "Sixteen chronic renal failure patients on acetate dialysis were orally administered 1,200 mg of L-carnitine chloride per day for 12 weeks." | ( Kobayakawa, H; Maeda, K; Shinzato, T, 1989) |
| "Three haemodialyzed chronic renal failure patients with histologically proven osteomalacia due to aluminium toxicity were treated with repeated injections of desferrioxamine, a potent chelator of aluminium." | ( Accominotti, M; Chapuy, MC; Charhon, SA; Chavassieux, P; Meunier, PJ; Traeger, J, 1986) |
| "Five male children with chronic renal failure (CRF) and growth retardation were treated with recombinant human GH (somatrem) three times weekly for 6 months." | ( Fine, RN; Koch, VH; Lippe, B; Sherman, BM, 1988) |
| "Fifteen patients with chronic renal failure commencing CAPD treatment were studied by a sensitive ferrokinetic technique." | ( Cavill, I; Coles, GA, 1986) |
| "Forty-five children with stable chronic renal failure, not on dialysis, were treated conservatively with a regimen of mild dietary phosphate restriction and high-dose phosphate binders for up to 5 years." | ( Chantler, C; Haycock, GB; Mak, RH; Rigden, SP; Start, KM; Tamanaha, K; Turner, C, 1987) |
| "Eight patients with chronic renal failure before the stage of dialysis (Group 1), 11 patients on regular dialysis treatment (Group 2) and 14 healthy control subjects (Group 3) were studied before, during and after angiotensin II (AII)-infusion." | ( Christensen, NJ; Danielsen, H; Jespersen, B; Pedersen, EB; Sørensen, SS, 1988) |
| "The pathophysiology of the anemia of chronic renal failure (CRF), erythropoietin physiology, the characteristics of recombinant human erythropoietin, and the results of nearly 2 years of therapy with this product in hemodialysis patients are detailed in this review." | ( Adamson, JW; Eschbach, JW, 1988) |
| "In advanced chronic renal failure the hypozincemia is more markedly during conservative therapy, than in patients treated by chronic hemodialysis." | ( Prehn, B, 1988) |
| "Fourteen patients with chronic renal failure were studied during two successive dialysis treatments for which either acetate or bicarbonate were used as a buffer anion in the dialysate." | ( Bahner, U; Burghardt, W; Heidland, A; Kasper, H; Keller, F; Kortmann, B; Scheppach, W; Teschner, M, 1988) |
| "Similarly, 9 patients with chronic renal failure who were not undergoing haemodialysis showed pre- and post-treatment urinary NAG concentrations of 8." | ( Hatano, M; Iwabuchi, F; Nagura, Y; Shimada, A; Takahashi, S, 1988) |
| "In the Phase II study, 66 patients with chronic renal failure on maintenance hemodialysis with less than 20% hematocrit values were treated with rhEpo in doses of 50 U/kg to 200 U/kg two or three times a week." | ( Koshikawa, S; Kubo, K; Mimura, N; Mizoguchi, H; Nihei, H; Ota, K; Shimizu, N; Takaku, F; Tanaka, K; Urabe, A, 1988) |
| "Five patients with chronic renal failure, complicated by bone aluminum toxicity, were treated with deferoxamine (DFO)." | ( Boykin, JL; Sherrard, DJ; Walker, JV, 1988) |
| "In 7 anuric patients with chronic renal failure treated by hemodialysis for a period from 36 up to 73 months a programmed drawing out of fluids was applied by using a dialyzing solution with variable sodium concentration in order to avoid heavy hypotensive incidents." | ( Antonov, S; Kiriakov, Z; Krivoshnev, S; Kuleva, V; Vŭzelov, E, 1988) |
| "In 57 patients with chronic renal failure (CRF) [44 patients on regular dialysis treatment (RDT), 33 renal transplant patients (RT) and 26 normal patients (NP)] and in a further 11 patients with CRF (8 patients on RDT and 17 patients without any renal disease in the post mortem) the vitamin A content of the serum obtained from the tissue of the liver, the stomach, the subcutaneous adipose tissue and the bone were analyzed." | ( Abendroth, K; Fünfstück, R; Geinitz, D; Keil, E; Kokot, F; Schöne, S; Sperschneider, H; Stein, G, 1986) |
| "Twenty children with chronic renal failure never had hyperkalemia, and both renin and aldosterone were normally stimulated by intravenous administration of furosemide, whereas three patients had moderate hyperkalemia (serum potassium concentration between 5." | ( Castillo, G; Oliveros, R; Rodríguez-Soriano, J; Sanjurjo, P; Vallo, A, 1986) |
| "Dietary therapy in chronic renal failure emphasizes the goal of avoiding the metabolic problems--particularly those relating to excess dietary protein and phosphorus." | ( Holliday, MA, 1986) |
| "We report on a patient suffering from chronic renal failure, who developed hemorrhagic bullous pemphigoid while being treated with Furosemide." | ( David, M; Feuerman, EJ; Ingber, A, 1986) |
| "In 10 patients in the polyuric stage of chronic renal failure without dialysis treatment during Giordano-Giovanetti-Maggiora diet with addition of sodium chloride the urinary excretion of sodium increased but that of vitamin C was not influenced." | ( Derzsiová, K; Mydlík, M; Pribylincová, V; Takác, M; Zvara, V, 1986) |
| "Eighteen patients with chronic renal failure (serum creatinine 173-756 mumol/l) and hyperlipidemia were treated with gemfibrozil (1200 mg/day)." | ( Korte, T; Kuusi, T; Pasternack, A; Solakivi, T; Vänttinen, T, 1987) |
| "Five children with chronic renal failure and severe rachitic deformities of the lower limbs were treated with 1 alpha-hydroxyvitamin D (1 alpha-OHD3) for 16 to 53 months." | ( Blockey, NJ; Mocan, H; Murphy, AV, 1986) |
| "A patient with chronic renal failure and secondary hypertension was treated with captopril." | ( Israeli, A; Leitersdorf, E; Or, R, 1985) |
| "Rats with chronic renal failure display reduced pressor response to NE administration, but this derangement can be prevented by prior parathyroidectomy and abolished by administration of indomethacin." | ( Campese, VM; Iseki, K; Massry, SG, 1985) |
| "To study its pharmacokinetics in chronic renal failure, we administered a single oral dose of 400 mg to 14 patients and 6 controls with normal renal function." | ( Arrigo, G; Broccali, G; Cavaliere, G; D'Amico, G; Passarella, E, 1985) |
| "Seven patients with chronic renal failure treated with haemodialysis for 4 to 24 months were found to have low exchangeable potassium levels." | ( Seedat, YK, 1969) |
| "In 16 patients with chronic renal failure and osteomalacia resistant to vitamin-D therapy, aluminium was demonstrated in bone biopsy specimens at the interface between thickened osteoid and calcified bone by means of both X-ray microanalysis and a specific histochemical stain." | ( Beastall, G; Boyce, BF; Boyle, IT; Elder, HY; Elliot, HL; Fell, GS; Fogelman, I; Junor, BJ, 1982) |
| "In 14 patients affected by chronic renal failure (7 males and 7 females) it has been evaluated the secretion of beta LPH, beta EP, ACTH and Cortisol in basal conditions and immediately after a dialytic treatment." | ( De Leo, M; De Leo, V; De Luca, S; Facchinetti, F; Genazzani, AR; Parrini, D; Petraglia, F; Verzetti, G, 1982) |
| "In a 74-year-old man with chronic renal failure, Clomethacine therapy was followed, on two different occasions, by transient exacerbation of renal failure." | ( Labram, C; Perotin, D, 1983) |
| "In 17 patients with chronic renal failure treated by haemodialysis and with arterial hypertension, PRA was likewise determined before and after injecting furosemide." | ( Rotnáglová, Z; Stríbrná, J; Zabka, J, 1981) |
| "We treated 24 patients who had chronic renal failure with a low-phosphorus diet containing 20 to 30 g of mixed-quality protein, supplemented by amino acids and their keto analogues." | ( Hill, S; Mitch, WE; Steinman, TI; Tungsanga, K; Walser, M; Zeger, S, 1984) |
| "While patients of chronic renal failure can survive today for a long period thanks to the spread of hemodialysis, establishment of criteria for the treatment of renal hyperparathyroidism is an important problem." | ( Maeda, M, 1984) |
| "19 nondialyzed pediatric patients with chronic renal failure and renal osteodystrophy participated in a 4- year prospective trial of the effects of 25-hydroxycholecalciferol (25-OHD3) in the treatment and prevention of clinical symptoms of renal osteodystrophy." | ( Mazur, AT; Norman, ME, 1984) |
| "Fourteen patients with chronic renal failure treated with hemodialysis received intermittent plasmapheresis with the purpose of treating skin pruritus and polyneuropathy." | ( Dvoretskiĭ, LI; Granich, LP; Vorob'ev, PA, 1984) |
| "ātients with end-stage chronic renal failure (CRF) and those receiving dialysis therapy have normal or decreased serum total T4 (TT4), reduced serum total T3 (TT3), and normal total reverse T3 (TrT3) levels." | ( Feinstein, EI; Kaptein, EM; Massry, SG; Nicoloff, JT, 1983) |
| "Two patients in chronic renal failure receiving amiodarone for the treatment of refractory arrhythmias were commenced on dialysis, in one case, intermittent peritoneal dialysis, in the other, haemodialysis." | ( Harris, L; Hind, CR; Holt, DW; Krikler, SJ; McKenna, WJ; Savage, C; Storey, GC, 1983) |
| "Patients with chronic renal failure requiring maintenance hemodialysis at the end of pregnancy are not as uncommon as pregnant women previously treated by this therapy." | ( André, M; Beuve Méry, P; Muller, G; Ryckelynck, JP, 1983) |
| "27 patients with chronic renal failure, 21 patients on chronic intermittent dialysis treatment and 27 healthy controls were tested for serum level of vitamin E estimated spectrophotometrically." | ( Fünfstück, R; Günther, K; Richter, G; Sperschneider, H; Stein, G, 1983) |
| "Patients with predialysis chronic renal failure and bone disease were treated with 1 alpha-hydroxy-derivatives of vitamin D." | ( Birkenhäger, JC; Birkenhäger-Frenkel, DH; Juttmann, JR; van Krimpen, C; Visser, TJ, 1983) |
| "A patient receiving hemodialysis for chronic renal failure had neutropenia six weeks after administration of his last dose of intravenous vancomycin and in the absence of other drug therapy." | ( Farwell, AP; Glew, RH; Kendall, LG; Vakil, RD, 1984) |
| "Patients with chronic renal failure who have not yet received dialytic therapy may develop a symptom complex progressing from mild sensorial clouding to delirium and coma, with tremor, asterixis, multifocal myoclonus, and seizures." | ( Arieff, AI; Mahoney, CA, 1982) |
| "A patient with chronic renal failure who experienced symptomatic ventricular tachycardia was treated successfully with procainamide (PA) after numerous dosage adjustments to optimize his clinical response and serum PA and NAPA concentrations." | ( Batenhorst, RL; Bottorff, MB; Kuo, CS, 1983) |
| "A patient with sarcoidosis and chronic renal failure was treated for hyperphosphatemia with aluminum hydroxide." | ( Caruana, RJ; Weinstein, RS, 1983) |
| "The effects of chronic renal failure (CRF) and corticosteroid treatment on the aortic uptake of labelled free and esterified cholesterol (FC and EC) were investigated in normocholesterolemic rabbits." | ( Nielsen, M; Szpirt, W; Tvedegaard, E, 1983) |
| "In ten non dialyzed patients with chronic renal failure, 18 patients on regular dialysis treatment and 70 renal transplant recipients alpha-1-antitrypsin and fibrinogen levels were investigated." | ( Balcke, P; Hysek, H; Kopsa, H; Lenz, K; Schmidt, P; Zazgornik, J, 1981) |
| "Twelve patients with chronic renal failure and osteitis fibrosa were treated for periods of 1-9 months with thrice-weekly injections of 10-200 iu salmon calcitonin." | ( Cundy, T; Earnshaw, M; Heynen, G; Kanis, JA; Paton, S; Woods, CG, 1982) |
| "A patient with tuberculoid leprosy and chronic renal failure was given a renal allograft after 5 months of dapsone (DDS) treatment." | ( Date, A; Mathai, R; Pandey, AP; Shastry, JC, 1982) |
| "We conclude that in patients with chronic renal failure, the dose of digoxin should be decreased by 50% if quinidine therapy is initiated." | ( Fenster, PE; Graves, PE; Hager, WD; Michael, UF; Perrier, D; Powell, JR, 1982) |
| "administered to 13 patients with chronic renal failure (mean creatinine clearance 46." | ( Boner, G; Rosenfeld, JB; Wainer, E; Wittenberg, C, 1981) |
| "Some specimens from patients with chronic renal failure treated by haemodialysis showed elevated values." | ( Michaelis, HC; Thomas, L; Walb, D; Winckelmann, M, 1981) |
| "In 20 patients suffering from chronic renal failure treated by hemodialysis (CRFH) the pure pancreatic juice (PPJ) collected via endoscopic cannulation of the papilla was studied." | ( Frayssinet, R; Multigner, L; Murisasco, A; Sahel, J; Saingra, S; Sarles, H, 1981) |
| "In 57 children with chronic renal failure (19 on conservative treatment, 25 haemodialysis and 13 after transplantation) body iron stores were determined by an immunoradiometric assay with a heterologous antibody system in relation to haemochromatosis alleles, HLA A3 and B7." | ( Lenhard, V; Müller-Wiefel, DE; Schärer, K, 1981) |
| "40 patients with bone disease due to chronic renal failure have been treated with 1 alpha-hydroxyvitamin D3 or 1,25-dihydroxyvitamin D3 for a total of 750 patient-months." | ( Cundy, T; Earnshaw, M; Heynen, G; Kanis, JA; Russell, RG; Smith, R; Woods, CG, 1980) |
| "In patients with chronic renal failure digoxin administration induced a reduction in QS2, PEP and PEP/LVET ratio and a prolongation of LVET (P < 0." | ( Luciak, M; Trznadel, K; Wyszogrodzka, M, 1980) |
| "In 8 patients with chronic renal failure (CRF) on hemodialysis combined therapy (erythropoietin+calcitriol) effect was evaluated versus control group of 9 hemodialysis patients on erythropoietin monotherapy." | ( Klepikov, PV; Kukhtevich, AV; Lashutin, SV; Nikolaev, AIu, 1995) |
| "Six patients with chronic renal failure (glomerular filtration rate 18 +/- 2 ml/min) underwent two 10-day admissions separated by at least 1 yr of outpatient therapy with a very low-protein diet (VLPD) providing 0." | ( Akpele, L; Chapman, T; Maroni, BJ; Masud, T; Tom, K; Young, VR, 1995) |
| "In 10 patients with chronic renal failure treated with haemodialyses (HD) T and B cell populations were determined in peripheral blood, together with immunoglobulin concentration and NBT test in the first two hours of the procedure using cuprophan and cellulose acetate dialysers." | ( Bartelik, S; Heltman, H; Partyka, M; Sarnecka, S; Starzyk, J, 1993) |
| "In patients with chronic renal failure treated with haemodialysis many disorders of specific and unspecific immunity were observed." | ( Cichoń, R; Grzeszczak, W; Moczulski, D; Religa, Z; Szydłowska, I; Zukowska-Szczechowska, E, 1994) |
| "Survival after ESRD onset is longer in blacks than in whites treated with dialysis, even after adjusting for comorbidity and other factors that affect survival." | ( Cowie, CC; Harris, MI; Port, FK; Rust, KF, 1994) |
| "Treatment commenced after chronic renal failure had been present for seven weeks." | ( Clark, RG; Gillespie, CM; Hazel, SJ; Jureidini, KF; Martin, AA; Moore, RJ, 1994) |
| "We studied 716 patients treated for ESRD and 361 control subjects of similar age from Maryland, Virginia, West Virginia, and Washington, D." | ( Klag, MJ; Perneger, TV; Whelton, PK, 1994) |
| "In a double-blind study, 24 ESRD patients with LVH were randomized to 12 months' administration of either the angiotensin-converting enzyme (ACE) inhibitor perindopril (n = 14) or the calcium channel blocker nitrendipine (n = 10)." | ( Cuche, JL; Guerin, AP; London, GM; Marchais, SJ; Pannier, B; Safar, ME, 1994) |
| "63 patients with chronic renal failure (pnn, 23 treated without dialyses and 40 with dialyses) as well as 20 healthy subjects were studied." | ( Grzeszczak, W; Kowalska, K; Kowalski, D, 1994) |
| "Two groups of patients with terminal chronic renal failure (TCRF) treated from 1970 to 1979 (group 1) and in 1980-1989 (group 2) have been compared in respect to treatment results." | ( Briukhovetskiĭ, AG; Burtsev, VI; Grankin, VI; Klopotskiĭ, SA; Miasnikova, EB, 1993) |
| "Men with chronic renal failure treated by haemodialysis have raised levels of bioactive LH (B-LH) and immunoreactive LH (I-LH) but reduced B-LH:I-LH (B:I) ratio and testosterone (T) secretion." | ( Bauerfeld, C; Mitchell, R; Robertson, WR; Schaefer, F; Schärer, K, 1994) |
| "In 8 subjects with chronic renal failure treated conservatively the renal hippurate clearance (CHip), polyfructosan (CPF) and creatinine (Ccr) clearance was assessed." | ( Dzúrik, R; Nádvorníková, H; Schück, O; Skibová, J; Spustová, V; Teplan, V, 1994) |
| "Following parathyroidectomy (PTX), in chronic renal failure patients a 94% fall in serum intact iPTH and a decline of serum calcium to hypocalcemic levels requiring calcitriol administration were observed." | ( Chicca, S; Coen, G; De Antoni, E; DiSanza, P; Manni, M; Mazzaferro, S; Onorato, L; Sardella, D; Spurio, A; Trombetta, M, 1994) |
| "RBCs were transfused to patients with ESRD and secretion of cytokines was measured before, and 4 hours, 4, 7 and 14 days afterwards; patients with ESRD received recombinant human erythropoietin (rHuEpo) and secretion of cytokines was measured before treatment and two and four months later." | ( Gafter, U; Kalechman, Y; Levi, J; Orlin, JB; Sredni, B, 1994) |
| "We studied 201 end-stage renal disease (ESRD) patients sustained on maintenance hemodialysis (MD) (n = 164) and chronic ambulatory peritoneal dialysis (CAPD) (n = 37) to determine (1) the frequency of acute attacks of gouty arthritis (GA) in those ESRD patients who had GA before dialytic therapy, and (2) the incidence of new-onset GA in hyperuricemic long-term (> 12 years) ESRD patients on MD." | ( Delano, BG; Dulin, AL; Friedman, EA; Ifudu, O; Tan, CC, 1994) |
| "The anemia in patients with chronic renal failure can be corrected through treatment with recombinant human erythropoietin treatment." | ( Haedersdal, C; Jeppesen, L; Mehlsen, J; Nielsen, B; Stenver, D; Winther, K, 1994) |
| "We treated pre-dialysis ESRD patients with recombinant human erythropoietin (rHuEPO) by either the subcutaneous (s." | ( Sakamoto, N; Watanabe, Y; Yamazaki, C, 1993) |
| "Nine patients with anemia of chronic renal failure were treated with recombinant human erythropoietin (rHuEPO) in dose 50-150 IU/kg/week." | ( Brabec, V; Cermák, J; Gregora, E; Lachmanová, J, 1994) |
| "In patients with chronic renal failure on regular dialysis treatment, limboconjunctival degenerations and calcifications are commonly observed." | ( Klaassen-Broekema, N; van Bijsterveld, OP, 1993) |
| "Drug dosage in end-stage renal disease (ESRD) patients undergoing haemodialysis is a very complex problem because of numerous variables relating to the patient, the type of drug administered and the type of dialysis and dialyser." | ( Dominguez-Gil, A; Mac-Kay, MV; Martinez-Lanao, J; Sanchez Burson, J, 1993) |
| "Anemia in patients with chronic renal failure (CRF) is multifactorial, and while the majority will respond to the paternal administration of recombinant human erythropoietin (r-HuEPO), a role for coexistent plasma inhibitors and stimulators, such as burst-promoting activity (BPA), remains controversial." | ( Jacobs, P; Meyer, J; Randall, G; Swanepoel, C, 1993) |
| "A 60-year-old male with chronic renal failure undergoing hemodialysis was treated with combination chemotherapy with carboplatin and etoposide against stage IV adenocarcinoma of the lung." | ( Bando, H; Shinohara, T; Sumitani, H; Takishita, Y; Tanaka, H; Yanagawa, H, 1993) |
| "A 35-year-old man with chronic renal failure developed toxic epidermal necrolysis due to combination antibiotic therapy for a community acquired pneumonia." | ( Brosius, FC; Garner, WL; Rodriguez, JL; Smith, DJ; Thomson, PD, 1993) |
| "52 patients with chronic renal failure treated with haemodialysis and 21 healthy subjects were observed." | ( Grzeszczak, W; Jedryczko, A; Kamińska-Galwas, B; Pachelski, J, 1993) |
| "In the anaemia of chronic renal failure (ACRF) treatment with recombinant human erythropoietin (r-Hu-EPO) has been shown to be effective in both improvement of the anaemia and increase in quality of life." | ( Frenken, LA; Koene, RA; Vreugdenhil, G, 1993) |
| "Long term treatment of ESRD patients with epoetin does not significantly alter the pharmacokinetic profile of the drug." | ( Bäumer, K; Gladziwa, U; Klotz, U; Mann, H; Sieberth, HG; Zollinger, R, 1993) |
| "A prospective study was undertaken of 10 chronic renal failure patients on Continuous Ambulatory Peritoneal Dialysis (CAPD) complicated by repeated bouts of peritonitis treated with gentamicin." | ( Aziz, NS; Gendeh, BS; Gibb, AG; Kong, N; Said, H; Zahir, ZM, 1993) |
| "Patients with chronic renal failure (CRF) and haemodialysis treatment usually have a reduced CO transfer factor." | ( Guenard, H; Moinard, J, 1993) |
| "Treatment of ESRD-related anemia with EPO significantly improved the QL of hemodialysis patients." | ( Aracil, FJ; Moreno, F; Pérez, R; Valderrábano, F, 1996) |
| "Of the 372 patients with chronic renal failure 139 had started regular dialysis treatment and 95 were dead, including 27 patients, with a mean age of 71 years, who died of untreated end-stage renal failure (ESRF)." | ( Bailey, RR; Buttimore, AL; Inkster, JA; Lynn, KL; Robson, RA; Smith, AH, 1996) |
| "Immune abnormalities in patients with chronic renal failure and those treated by dialysis contribute to high rates of morbidity and mortality." | ( Descamps-Latscha, B; Friedlander, MA; Jungers, P; Labrunte, M; Nguyen, AT; Verger, C; Witko-Sarsat, V; Wu, YC, 1996) |
| "We describe an elderly patient with chronic renal failure who developed bilateral exudative retinal detachments after initiation of systemic corticosteroid therapy, followed by prompt resolution of the retinal detachments after the corticosteroids were discontinued." | ( Desatnik, HR; Gutman, FA, 1996) |
| "Thirteen patients with chronic renal failure on regular haemodialysis and in need of treatment for anaemia were treated with 45-60 U/kg erythropoietin three times a week." | ( Bedíz, CS; Ergene, N; Eser, C; Gökbel, H; Türk, S; Uçok, K; Yeksan, M, 1996) |
| "Twelve prepubertal children with chronic renal failure (CRF) were treated with human growth hormone (GH) (1." | ( Brun, P; Czernichow, P; Loirat, C; Neol, M; Porquet, D; Rocchicioli, P; Simon, D, 1996) |
| "Three hypertensive patients with chronic renal failure treated with slow-release verapamil at the recommended doses for high blood pressure experienced acute deleterious effects shortly after treatment (6 h to 3 days)." | ( Alegría, E; Errasti, P; Huelmos, A; Purroy, A; Váquez, C, 1996) |
| "cyclophosphamide for LN progress to ESRD and a high serum Cr and a high degree of interstitial fibrosis on renal biopsy before treatment are associated with a worse renal prognosis." | ( Allen, NB; Conlon, PJ; Fischer, CA; Fleming, JA; Howell, DN; Levesque, MC; Smith, SR; St Clair, EW, 1996) |
| "The nutritional treatment of chronic renal failure with a low-protein low-phosphorus diet (conventional low-protein diet, CLPD) is effective in reducing uremic intoxication, slowing the progression of renal failure and preventing secondary hyperparathyroidism." | ( Barsotti, G; Cupisti, A; Dani, L; Giovannetti, S; Meola, M; Morelli, E, 1996) |
| "Elevated plasma porphyrin levels in ESRD patients are caused by lack of urinary excretion and the inability of haemodialysis and CAPD therapy to remove them." | ( Gafter, U; Korzets, A; Malachi, T; Mamet, R; Schoenfeld, N, 1996) |
| "We measured the quality of life of 21 ESRD patients before and after 6 months of exposure to treatment with high-efficiency hemodialysis with bicarbonate (HEHD/bicarbonate)." | ( Arredondo, A; Calderon, C; De Icaza, E; Hernandez, G, 1997) |
| "In the present study we induced chronic renal failure by administration of lithium for 16 weeks to new-born rats, and examined the spontaneous course of this nephropathy and the effects of antihypertensive treatment with either perindopril (12 mg/kg diet) or hydrochlorothiazide (500-1000 mg/kg diet) during a 24 weeks follow up period without lithium." | ( Christensen, S; Hansen, AK; Marcussen, N; Shalmi, M, 1997) |
| "Ten patients with chronic renal failure from different genesis (serum creatinine levels 150-200 mumol/l), were evaluated from the aspect of the effect of the diuretic therapy." | ( Cakalaroski, K; Grozdanovski, R; Ivanovski, N; Polenakovic, M; Ristovska, V, 1997) |
| "In the majority of patients with chronic renal failure and in patients during various forms of renal replacement therapy can develop vitamin B6 deficiency from many causes." | ( Derzsiová, K; Mydlík, M; Zemberová, E, 1997) |
| "Atracurium is administered to ten chronic renal failure patients in the course of kidney transplantation, abiding to all requirements and doses recommended by the company." | ( Bovianska, N, 1997) |
| "The clinical picture in chronic renal failure (CRF) shows great variability depending on age, sex, aetiology of disease, grades of renal injury and type of treatment." | ( Duma, D; Janicka, L; Kimak, E; Solski, J; Zagojska, M, 1997) |
| "In 9 patients with chronic renal failure treated by HD with bicarbonate-35 mEq/l containing fluid, investigations of minute ventilation, breathing patterns and blood gases were done during 5 sequential HD." | ( Wanic-Kossowska, M, 1997) |
| "In the treatment of anemia of chronic renal failure, the most common cause of recombinant human erythropoietin (rhEPO) resistance is iron deficiency." | ( Ahsan, N, 1998) |
| "Controls were six patients with chronic renal failure but not on regular dialysis treatment (CRF) and six healthy subjects (N)." | ( Dal Canton, A; De Simone, W; Gregorini, M; Guallini, P; Libetta, C; Rampino, T; Ranghino, A; Soccio, G; Tamagnone, L, 1998) |
| "In a group of 66 patients with chronic renal failure having regular dialyzation treatment the serum concentration of endogenous erythropoietin (EPO), haemoglobin levels (Hb), haematocrit (Ht) and serum creatinine (Cr) were assessed." | ( Bachleda, P; Zadrazil, J; Zahálková, J, 1997) |
| "We have investigated the incidence of chronic renal failure and its risk factors in our transplant population, which was treated predominantly with cyclosporine." | ( Fisher, NC; Gunson, BK; Lipkin, GW; Neuberger, JM; Nightingale, PG, 1998) |
| "Other factors related to chronic renal failure and/or dialysis treatment might lead to endothelial dysfunction, which is associated with an adverse cardiovascular outcome." | ( Donker, AJ; Janssen, MJ; Lambert, J; Stehouwer, CD; Steyn, M; van Guldener, C, 1998) |
| "Her hypermagnesemia might be caused by chronic renal failure with hypocalcemia and administration of magnesium sulfate as a cathartic." | ( Kunitoku, N; Kunitoku, Y; Sakanashi, Y; Terasaki, H; Ushijima, K, 1998) |
| "Normal subjects and chronic renal failure patients either not on dialysis or on regular dialysis treatment served as controls." | ( Dal Canton, A; Esposito, C; Fornoni, A; Libetta, C; Rampino, T; Semeraro, L, 1998) |
| "In 50 patients with chronic renal failure treated by HD and in 13 nondialyzed patients EMG and measurement of nerve conduction velocity were performed." | ( Bombicki, K; Czarnecki, R; Kozioł, L; Wanic-Kossowska, M, 1998) |
| "One hundred and five chronic renal failure patients were divided randomly into two groups, 75 cases of Niaodujing (NDJ) treatment group and 30 cases of control group treated with aldehyde coated oxystarch." | ( Cheng, XX; Wang, YJ; Xu, L, 1996) |
| "We report the case of a patient with chronic renal failure on hemodialysis for 9 years who was treated for small-cell lung cancer." | ( Clavier, J; Daniel, C; Gouva, S; Guillodo, MP; Guillou, B; Robinet, G, 1998) |
| "Eleven patients with chronic renal failure who were being treated with haemodialysis three times a week were monitored for a total of 34 haemodialysis sessions." | ( Andersen, EM; Jensen, HA; Jørgensen, LG; Nielsen, AL, 1998) |
| "In 23 patients with chronic renal failure (CRF), 23 patients on chronic intermittent hemodialysis treatment (DP), 22 patients after renal transplantation (RT) and 40 normal persons (NP), Biotin plasma levels and the urinary excretion were analysed and compared to the dietary Biotin intake." | ( Bitsch, R; Helbich-Endermann, M; Jung, U; Schneider, S; Stein, G, 1998) |
| "We also studied the effect of chronic renal failure on the plasma concentration of AcSDKP during long-term ACE inhibitor (ACEI) treatment or in its absence." | ( Azizi, M; Ezan, E; Gerineau, V; Ménard, J; Reny, JL; Wdzieczak-Bakala, J, 1999) |
| "Renal osteodystrophy complicated chronic renal failure presents many clinical problems because of multiple pathogenetic factors, non specific clinical symptoms as well as not precisely enough methods evaluating progress and treatment efficacy of this complications." | ( Nowak, Z, 1998) |
| "Vital, end-stage renal disease (ESRD), and BP status and treatment beyond completion of the 2-yr trial were determined." | ( Bergstralh, EJ; Dart, RA; Donadio, JV; Grande, JP; Larson, TS; Spencer, DC, 1999) |
| "Optimized anemia therapy in ESRD requires individualized and specific application of epoetin and iron for each patient, and significant cost savings can result from such a strategy." | ( Besarab, A; Frinak, S; Yee, J, 1999) |
| "Sixteen prepubertal patients with chronic renal failure (CRF) were given daily recombinant human growth hormone (rhGH) treatment (1." | ( Baudouin, V; Czernichow, P; Loirat, C; Maisin, A; Remesy, M; Rosilio, M; Simon, D, 1999) |
| "Fifteen children with chronic renal failure from early infancy who did not require renal replacement therapy were followed for 3 years." | ( Bilem, N; Proesmans, W; Van Dyck, M, 1999) |
| "Thus, the relative risk of events (ESRD) between conventional and ramipril-treated men was higher in subjects with the DD genotype (1." | ( Benini, R; Gherardi, G; Perna, A; Remuzzi, G; Ruggenenti, P; Testa, A; Zoccali, C, 2000) |
| "Of new Dutch ESRD patients, 365 were consecutively included in this study at the start of their chronic dialysis treatment." | ( Boeschoten, EW; Dekker, FW; Jansen, MA; Korevaar, JC; Krediet, RT, 1999) |
| "Whether rHuEpo treatment in ESRD is accompanied by alterations in NO production was explored in patients undergoing hemodialysis." | ( Acchiardo, SR; Cardenas, R; Kang, ES; Mishra, S; Tevlin, MT; Wang, YB, 2000) |
| "Intermittently hemodialyzed ESRD patients treated with rHuEpo accumulate less NOx in the plasma before dialysis but generate more NOx during dialysis than untreated patients." | ( Acchiardo, SR; Cardenas, R; Kang, ES; Mishra, S; Tevlin, MT; Wang, YB, 2000) |
| "The model of chronic renal failure (CRF) was made in 5/6 nephrectomized rats and Huangdan capsule was used to treat these rats." | ( Chen, J; Chen, S; Hong, S; Zhang, C; Zheng, J, 1998) |
| "Thirteen patients with ESRD on intermittent haemodialysis treatment, six patients with chronic renal failure not yet on dialysis, and 15 age- and sex-matched healthy controls were examined." | ( Galle, PR; Himmelsbach, F; Märker-Hermann, E; Schreiner, O; Wandel, E, 2000) |
| "iron as monotherapy for anemia in ESRD patients." | ( Vogel, S, 2000) |
| "Patients with multiple myeloma (MM) and chronic renal failure have generally been excluded from myeloablative therapy programs followed by hematopoietic stem cell support because of the potential increase in transplant-related morbidity and mortality." | ( Benni, M; Cavo, M; Motta, MR; Rizzi, S; Ronconi, S; Tosi, P; Tura, S; Zamagni, E, 2000) |
| "We hypothesized that in patients with chronic renal failure, a condition associated with both hyperhomocysteinemia and atherosclerosis, treatment with folic acid would improve endothelial function." | ( Jones, HJ; Landray, MJ; McGlynn, FJ; Thambyrajah, J; Townend, JN; Wheeler, DC, 2000) |
| "The time to end-stage renal disease (ESRD) was predicted by two different models based on the rate of glomerular filtration rate decline (DeltaGFR) and incidence of ESRD (events) measured during the Ramipril Efficacy in Nephropathy Trial in 117 and 166 patients, respectively, randomized to comparable blood pressure control with ramipril or conventional therapy." | ( Benini, R; Garattini, L; Pagano, E; Remuzzi, G; Ruggenenti, P; Tammuzzo, L, 2001) |
| "In long term studies, the risk of ESRD in treated hypertensives is between 1." | ( Fauvel, JP; Laville, M, 2001) |
| "In patients with chronic renal failure, three kinds of treatments can slow the progression of renal insufficiency: optimal control of blood pressure; use of converting enzyme inhibitors; low-protein diet." | ( Ronco, P; Rossert, J, 2001) |
| "Medical therapy for ESRD and secondary hyperparathyroidism has evolved to include better dialytic urea removal and the use of calcitriol." | ( Adams, ME; Ashley, BA; Bienemann, ME; Cohen, EP; Decker, PA; Demeure, MJ; Doffek, KM; Wilson, SD; Zhu, YR, 2001) |
| "Fifteen males with chronic renal failure who were not receiving hemodialysis and 25 male renal failure patients with uremia who were undergoing hemodialysis were enrolled before and after rhuEPO therapy." | ( Jeng, FR; Lin, SL; Wu, SC, 2001) |
| "We present here 2 patients with chronic renal failure in whom treatment for hypothyroidism resulted in a significant and sustained reduction of their serum creatinine levels." | ( Horita, Y; Inenaga, T; Nakahama, H; Nakamura, S; Sakaguchi, K; Sasaki, O; Takishita, S, 2001) |
| "Patients with chronic renal failure (CRF) have impaired exercise capacity even after erythropoietin treatment." | ( Campistol, JM; Casademont, J; Marrades, RM; Masanés, F; Miró, O; Roca, J; Sala, E; Torregrosa, V; Wagner, H; Wagner, PD, 2001) |
| "The occurrence of chronic renal failure in strict relationship with maternal nimesulide assumption in this case is strongly suggestive for a pharmacological damage, either direct or mediated by renin angiotensin inhibition, and possibly modulated by genetic factors, likely to account for the different outcome of similarly treated patients." | ( Amore, A; Conti, G; Coppo, R; Gianoglio, B; Peruzzi, L; Porcellini, G, 2001) |
| "In this study, 15 patients with chronic renal failure were treated only with doxazosin and diuretics for 6 months and their blood pressure, renal parameters and lipid profile were measured." | ( Amano, K; Fujiyama, S; Hasegawa, T; Iba, O; Iwasaka, T; Kosaki, A; Masaki, H; Matsubara, H; Mori, Y; Nose, A; Okigaki, M; Shibasaki, Y; Tanaka-Uchiyama, Y; Tateishi, E, 2001) |
| "58 Japanese ESRD patients undergoing renal replacement therapy in our institution were evaluated." | ( Arai, T; Hara, S; Hosoya, T; Kagami, S; Kawaguchi, Y; Shigematsu, T; Tsukada, T; Yamada, A; Yokoyama, K, 2001) |
| "The development of ESRD decreases survival, particularly in those patients treated with dialysis only." | ( Goldstein, RM; Gonwa, TA; Hays, SR; Klintmalm, GB; Levy, MF; Mai, ML; Melton, LB, 2001) |
| "A 40-year-old woman with chronic renal failure on hemodialysis who had FIGO stage III ovarian cancer was treated with debulking surgery and carboplatin/paclitaxel combination chemotherapy." | ( Aoki, Y; Kase, H; Kato, N; Kikuchi, M; Sato, T; Takaki, Y; Tanaka, K; Tomita, M; Watanabe, M, 2002) |
| "A bone marrow transplant recipient with chronic renal failure developed genital condylomas resistant to standard therapy." | ( Bellenger, P; Bienvenu, B; Devergie, A; Gluckman, E; Lebbé, C; Martinez, F; Morel, P; Rivet, J; Rybojad, M, 2002) |
| "A 73-year-old woman with chronic renal failure developed generalized muscular weakness and pain 6 days after the start of allopurinol treatment(200 mg/day)." | ( Hasegawa, T; Hosoya, T; Nemoto, T; Suzuki, T; Takase, H; Terawaki, H; Yoshimura, K, 2002) |
| "On the case of 48 old patient with chronic renal failure, treated with repeated hemodialyses, we described diagnostic and therapeutic problems of infected arterio-venous fistula of severe clinical course and rare epidemiology (Staphylococcus warneri)." | ( Dziekiewicz, M; Kade, G; Prokopiuk, M; Wańkowicz, Z; Wierzbicki, P, 2001) |
| "Thirty-seven ESRD patients (24 males, 13 females) on dialysis treatment (18 haemodialysis, 19 continuous ambulatory peritoneal dialysis) and 21 healthy subjects (seven males, 14 females) were examined." | ( Anderstam, B; Bárány, P; Bergström, J; Divino Filho, JC; Heimbürger, O; Lindholm, B; Qureshi, AR; Stenvinkel, P; Suliman, ME, 2002) |
| "Prevention of CHD in ESRD requires identification and treatment of coronary risk factors in chronic renal insufficiency (CRI)." | ( Beck, GJ; Coronado, BE; Greene, T; Kusek, JW; Levey, AS; Sarnak, MJ; Wang, SR, 2002) |
| "Five ESRD patients with ANCA-associated vasculitis and a relapsing course of their disease were treated." | ( de Groot, K; Haubitz, M, 2002) |
| "Treatment of the anemia of chronic renal failure with intravenous iron and erythropoietin is highly effective, but frequently leads to ferritin levels which are much higher than those seen in the general population." | ( Kirschbaum, B, 2002) |
| "In 206 ESRD patients (126 males) aged 52+/-1 years, we evaluated the relationship between survival and five estimates of nutritional status (S-albumin, subjective global assessment (SGA), lean body mass (LBM), body fat mass (FM) assessed by dual-energy X-ray absorptiometry, and handgrip strength (HGS)) close to start of renal replacement therapy (RRT)." | ( Barany, P; Chung, SH; Heimbürger, O; Lindholm, B; Stenvinkel, P, 2002) |
| "Six patients with chronic renal failure and acidosis underwent muscle biopsy before and after 1 month's treatment with sodium bicarbonate." | ( Bartlett, K; Goodship, TH; Graham, KA; Redfern, CP; Roberts, RG; Wilkinson, R, 2002) |
| "We treated a 34-year-old chronic renal failure patient who did not have hyponatremia but developed severe pontine myelinolysis demonstrated with MRI." | ( Benli, US; Can, U; Kilinç, M, 2002) |
| "End-stage renal disease (ESRD) patients treated with hemodialysis have a high mortality rate, which is largely due to inadequate dialysis." | ( Blahut, SA; Fink, JC; McClellan, WM; Soucie, M; Zhan, M, 2002) |
| "Occurrence of end stage renal disease (ESRD) according to World Health Organization (WHO) class was analysed, and patients were subdivided according to whether treatment included at least six pulses of intravenous (i." | ( Ellis, S; Griffiths, M; Isenberg, DA; MacGowan, JR, 2002) |
| "CYC developed ESRD compared with none out of 10 not treated with i." | ( Ellis, S; Griffiths, M; Isenberg, DA; MacGowan, JR, 2002) |
| "End stage renal disease (ESRD) patients are frequently noncompliant with phosphate binder therapy." | ( Bledsoe, AL; Kaplan, MR; McGowan, J; Stashenko, CL, 2002) |
| "The risk reduction in new cases of ESRD was calculated by combining type 2 diabetes population estimates for the EU with the percent absolute risk reduction of ESRD in patients treated with losartan as observed in RENAAL." | ( Brenner, B; Carides, GW; Gerth, WC; Hannedouche, T; Martinez-Castelao, A; Remuzzi, G; Shahinfar, S; Viberti, G, 2002) |
| "A patient with chronic renal failure (CRF) developed neuroleptic malignant syndrome (NMS) after administration of risperidone and levomepromazine." | ( Fukasawa, T; Hayashi, H; Kawakatsu, S; Otani, K; Watanabe, K, 2002) |
| "Elderly patients with consistent pre-ESRD epoetin treatment had lower risks for death in the first year of dialysis therapy after ESRD initiation." | ( Collins, AJ; Ebben, JP; Everson, SE; St Peter, WL; Xue, JL, 2002) |
| "The reduction in the number of ESRD days over 4 years in patients treated with losartan significantly decreased costs associated with ESRD by 7,438 euros per patient (CI 95%: 3,029 euros - 11,847 euros, p=0." | ( Durand Zaleski, I; Gaugris, S; Hannedouche, T; Passa, P; Rodier, M; Souchet, T, 2003) |
| "Seventy-five ESRD (25 treated and 15 non treated with rhEPO on HD), and (20 treated and 15 non treated with rhEPO on CAPD) patients participated in this study." | ( Bladek, K; Bulikowski, W; Pietrzak, I, 2002) |
| "Patients with chronic renal failure commonly suffer from a secondary form of complex dyslipidaemia, and may benefit from lipid-lowering treatment." | ( Dratwa, M; Lameire, NH; Lins, RL; Matthys, KE; Peeters, PC; Stolear, JC; Verpooten, GA, 2003) |
| "At early stages of ESRD, iPTH could be elevated and ACKD units play an important part its early detection and subsequent treatment." | ( Andrino, T; Bardón, E; Barril, G; Cigarrán, S; Díaz, A; Sanz, P; Selgas, R, 2003) |
| "Eight-hundred twenty-six patients with chronic renal failure (CRF) (94% receiving haemodialysis and 6% receiving peritoneal dialysis) previously maintained on stable recombinant human erythropoietin (r-HuEPO) therapy with stable hemoglobin (Hb) concentrations (mean Hb concentration = 11." | ( Hernández Jaras, J; Lladós, F; López de Novales, E; Martínez Castelao, A; Otero, A; Pallardó, L; Reyes, A; Tabernero, JM; Valdés, F, 2003) |
| "Treatment of the anemia of chronic renal failure with erythropoietin, when instituted together with vigorous metabolic control may slow the rate of renal function decline." | ( Kadomatsu, S; Perera-Chong, M; Tapolyai, M, 2003) |
| "Very few patients with chronic renal failure (CRF) can maintain a hemoglobin concentration > 12 g/dl without rHuEpo treatment." | ( Berger-Smyka, B; Bober, E; Grzebalska, AM; Ksiazek, A; Majdan, M; Mierzicki, P; Orłowska, A, 2003) |
| "Hyperphosphataemia in patients with chronic renal failure has traditionally been treated with calcium- and aluminium-containing phosphate binders." | ( Altmann, P; Henderson, J, 2003) |
| "Many end stage renal disease (ESRD) patients get their first nephrologic care under critical clinical conditions and without previous diagnosis of chronic renal failure (CRF), a situation even worse than the late referral of CRF patients for nephrologic treatment." | ( Abdulkader, RC; Burdmann, EA; Oliveira, GM; Zanetta, DM, 2003) |
| "All untreated controls progressed to ESRD, with a median renal survival of 146." | ( Burns, GC; Mohammed, NB; Sivak, SL; Visintainer, P; Wei, A; Williams, BA, 2003) |
| "Clinical studies in patients with chronic renal failure either receiving or not receiving dialysis have shown that darbepoetin alfa is equivalent to recombinant human erythropoietin in terms of increases in hemoglobin concentration, percentage of patients achieving target hemoglobin concentration and average time to reach target hemoglobin concentration, although darbepoetin alfa is administered less frequently (once weekly or every other week)." | ( Cases, A, 2003) |
| "Treatment of the anemia of chronic renal failure with exogenous recombinant human erythropoietin (rHuEpo) is well established." | ( Brimble, KS; Carlisle, EJ; Lambert, K; McKenna, P; Rabbat, CG, 2003) |
| "Three SCLC patients with chronic renal failure undergoing HD were treated with CBDCA (300 mg/m(2)) on day 1 and ETP (50 mg/m(2)) on days 1 and 3, followed by HD 1 h after completing the administration of anticancer agents on each day." | ( Gomi, K; Inoue, A; Kikuchi, T; Maemondo, M; Miki, M; Nukiwa, T; Saijo, Y; Sato, T; Suzuki, T, 2004) |
| "As children with acute and chronic renal failure often have multiple comorbid conditions requiring drug therapy, generalists, intensivists, nephrologists, and pharmacists need to be aware of the issues surrounding the management of drug therapy in pediatric patients undergoing renal replacement therapy." | ( Fivush, BA; Furth, SL; Neu, AM; Parekh, RS; Veltri, MA, 2004) |
| "End-stage renal disease (ESRD) is associated with moderately severe hyperhomocysteinemia that is incompletely normalized by oral folic acid therapy and vitamin B12." | ( Elian, KM; Hoffer, LJ, 2004) |
| "The prevalence of chronic renal failure (CRF)/end stage renal disease and the accessibility of long term renal replacement therapy in Jamaica were evaluated." | ( Barton, EN; Falconer, H; Gilbert, DT; James, J; Samuels, D; Sargeant, LA; Smikle, MF; Smith, F; Smith, R; Wilson, R; Yeates, C, 2004) |
| "33% of patients were treated due to chronic renal failure shorter than 1 year." | ( Chudek, J; Hołowiecka, A; Kania, M; Kopeć, P; Kukla, M; Kułach, A; Machała, L; Pyda, M; Rozmus, W; Szpak, S; Wiecek, A; Zarzecki, M, 2004) |
| "An 80-year-old man with chronic renal failure (CRF) had pure red cell aplasia (PRCA) 9 months after starting the subcutaneous administration of recombinant human erythropoietin alfa (rHuEPO-alpha)." | ( Ascani, S; Baccarani, M; Finelli, C; Lopez, A; Mandreoli, M; Santoro, A; Vianelli, N, 2004) |
| "The study was conducted on 80 chronic renal failure Iraqi patients who were admitted to the dialysis centers at Al-Kadhumiya, Baghdad, Al-Yarmouk and Al-Karama teaching hospitals, Baghdad, Iraq, during the period November 1999 through to July 2000 for peritoneal or hemodialysis therapy." | ( Al-Hashimi, AF; Al-Khazragi, AS; Mohammed, FH, 2004) |
| "End-stage renal disease (ESRD) patients undergoing hemodialysis treatment have reduced plasma L-carnitine levels; however, the relationship between dialysis age and carnitine status is poorly understood." | ( Elias, T; Evans, AM; Faull, RJ; Fornasini, G; Nation, RL; Prasad, S; Reuter, SE, 2004) |
| "Incidence of ESRD, hospitalizations for heart failure, withdrawals for adverse events, and proteinuria during losartan or conventional treatment were compared within three tertiles of baseline serum creatinine concentration (highest, 2." | ( Brenner, BM; Carides, GW; de Zeeuw, D; Dimitrov, BD; Hille, DA; Perna, A; Remuzzi, G; Ruggenenti, P; Shahinfar, S, 2004) |
| "Although most dietary attempts to treat chronic renal failure (CRF) and to decrease uremia recommend a protein restriction, another dietetic approach, based on dietary fibers (DF), can lead to the same urea-lowering effect by increasing urea-nitrogen (N) excretion in stool with a concomitant decrease of the total N quantity excreted in urine." | ( Alphonse, JC; Deteix, R; Younes, H, 2004) |
| "Children with chronic renal failure (CRF+GH, n=11) before and under rhGH therapy and pediatric renal-transplant recipients without rhGH therapy (Tx, n=33) served as controls." | ( Daniel, V; Mehls, O; Melk, A; Opelz, G; Tönshoff, B, 2004) |
| "Patients with chronic renal failure (CRF) have difficulties in compliance with their care and treatment." | ( Bozbas, H; Guz, G; Korkmaz, ME; Muderrisoglu, H; Ozin, MB; Tayfun, E; Yigit, F, 2004) |
| "A 59 year-old woman suffering from chronic kidney failure, treated for the past year by haemodialysis, was hospitalized for alteration in her general status of health and severe digestive problems." | ( Chakib, A; Hachim, K; Mortajil, F; Ramdani, B; Zaid, D, 2005) |
| "Forty-eight patients with ESRD under chronic HD treatment were included in the study." | ( Abayli, E; Akalin, T; Atilgan, G; Ayli, D; Ayli, M; Azak, A; Camlibel, M; Dede, F; Yüksel, C, 2005) |
| "Patients with acute renal failure or chronic renal failure treated with renal replacement therapy were excluded from this study." | ( Chudek, J; Kokot, F; Kopeć, P; Kukla, M; Mamcarz, E; Wiecek, A; Wnuk, Z; Zarzecki, M, 2004) |
| "Patients with anemia of chronic renal failure are treated with erythropoietin." | ( Brill-Almon, E; Casadevall, N; Dranitzki-Elhalel, M; Galun, E; Harati, M; Iaina, A; Kaplan, E; Liberman, Y; Lippin, Y; Mei-Zahav, C; Mizrachi, S; Podjarny, E; Shani, N; Zeira, E, 2005) |
| "Most patients with chronic renal failure have anemia, which can be corrected by recombinant human erythropoietin (rHuEpo) treatment." | ( Boris, G; Kogan, J; Oren, S; Sapojnikov, M; Turkot, S; Veksler, A; Yagil, Y, 2005) |
| "A total of 36 patients with ESRD were evaluated at different stages of the disease and under different treatment by using standard transcranial magnetic stimulation (TMS) parameters." | ( Bagnato, S; Battaglia, F; Buemi, M; Floccari, F; Girlanda, P; Grasso, G; Morgante, F; Quartarone, A; Rizzo, V; Romeo, A; Sant'Angelo, A, 2005) |
| "Patients with ESRD in conservative therapy showed a significant reduction of short-interval intra-cortical inhibition (SICI)." | ( Bagnato, S; Battaglia, F; Buemi, M; Floccari, F; Girlanda, P; Grasso, G; Morgante, F; Quartarone, A; Rizzo, V; Romeo, A; Sant'Angelo, A, 2005) |
| "The treatment of anemia in chronic renal failure has been revolutionized by the introduction of recombinant human EPO." | ( Canova, C; Santoro, A, 2005) |
| "In children with ESRD treated with dialysis reduced TAS coexists with enhanced intracellular oxidative stress in T lymphocytes." | ( Lewandowska-Stachowiak, M; Runowski, D; Stefaniak, E; Warzywoda, A; Zachwieja, J; Zaniew, M, 2005) |
| "HBV-related MN leads to ESRD in a significant proportion of patients before the advent of antiviral therapy." | ( Chan, KW; Ho, YW; Kung, NN; Lai, FM; Lai, KN; Leung, JC; Lui, YH; Tang, CS; Tang, S, 2005) |
| "A 75-year-old man with chronic renal failure and hyperlipidemia treated with bezafibrate (400 mg/day) for 1." | ( Arai, D; Ichikawa, H; Kawamura, M; Kuriki, A; Sugie, M, 2005) |
| "Mortality rates in patients with chronic renal failure (CRF) are high both before and after start of renal replacement therapy (RRT)." | ( Cohen, SS; Elinder, CG; Evans, M; Fored, CM; Fryzek, JP; McLaughlin, JK; Nyrén, O, 2005) |
| "Most dietary attempts to treat chronic renal failure (CRF) and to decrease uremia use a protein restriction." | ( Alphonse, JC; Demigné, C; Deteix, P; Egret, N; Gueret, C; Hadj-Abdelkader, M; Rémésy, C; Younes, H, 2006) |
| "Patients suffering from chronic renal failure (CRF) are exposed to increased oxidative stress generated by uremic toxins, factors connected with hemodialysis, chronic inflammatory state, lack of vitamins A, E and selenium, advanced age, and parenteral iron administration." | ( Chlubek, D; Ciechanowski, K; Dolegowska, B; Kwiatkowska, E; Millo, B; Stepniewska, J, 2006) |
| "Since many end stage renal disease (ESRD) patients experi inflammation, malnutrition, and anemia, the interplay of these processes should be considered in the approach to patients treated with erythropoietin (EPO)." | ( Bistrian, BR; Carey, LA, 2000) |
| "Patients with chronic renal failure (crf) treated by hemodialysis often have increased serum cTnl level without evidence of acute myocardial ischemia." | ( Czekalski, S; Kobelski, M; Kozioł, L; Pawliczak, E; Wanic-Kossowska, M, 2003) |
| "In patients with ESRD, responsiveness to epoetin was lower in T2 after a period of epoetin therapy discontinuation than in T1 epoetin trial." | ( Milutinović, S; Trkulja, V, 2006) |
| "In a rat model of chronic renal failure, the three receptor agonists decreased the serum creatinine and increased the glomerular filtration rate at 9 weeks following therapy." | ( Borovecki, F; Grasser, WA; Grgurevic, L; Orlic, I; Paralkar, VM; Rogic, D; Simic, P; Thompson, DD; Vukicevic, S, 2006) |
| "We studied 317 ESRD patients starting dialysis therapy." | ( Bárány, P; Heimbürger, O; Kalantar-Zadeh, K; Lindholm, B; Qureshi, AR; Stenvinkel, P; Suliman, M; Vonesh, EF, 2007) |
| "Patients with end-stage renal disease (ESRD) receiving hemodialysis (HD) treatment have a markedly shortened life expectancy in large part owing to cardiovascular disease (CVD), not explained by established risk factors." | ( Aslam, S; Leone, A; Santha, T; Wilcox, C, 2006) |
| "In end-stage renal disease (ESRD) patients undergoing dialysis following EPO administration, four studies reported a decrease in PRA levels whereas the remaining nine disclosed no change in PRA levels." | ( Epstein, M; Rosario, R, 2006) |
| "Patients with chronic renal failure treated with haemodialysis have vascular risk factors that, in the general population, are associated with increased prevalence of Alzheimer's disease (AD)." | ( Caramelo, C; de Yébenes, JG; Gil, A; López, MD; Rubio, I, 2006) |
| "We assessed oxidative stress in 35 chronic renal failure under conservative treatment (CRF), 50 hemodialysed (HD) and 30 renal transplant (RT) patients, and 31 age- and sex-matched healthy subjects." | ( Ben Abdallah, T; Ben Maiz, H; Feki, M; Fellah, H; Ghorbel, H; Hedhili, A; Kaabachi, N; Lacour, B; Massy, Z; Mebazaa, A; Souissi, M, 2006) |
| "An 83-year-old man with chronic renal failure being treated by hemodialysis was admitted because of a left hilar mass." | ( Goto, N; Har, K; Hisada, T; Shibuya, H, 2007) |
| "Major tissue loss, ESRD, DM, and nonambulatory status are all independent predictors of treatment with primary AMP as opposed to revascularization." | ( Abou-Zamzam, AM; Banta, JE; Bianchi, C; Gomez, NR; Killeen, JD; Molkara, A; Teruya, TH, 2007) |
| "A total of 474 subjects (71 chronic renal failure [CRF], 73 hemodialysis [HD], 25 Tx, and 305 controls) from Baqyiatallah Hospital, Tehran, Iran were recruited between April 2002 and March 2004 for evaluation of dyspepsia, excluding those receiving any HP-eradication therapy." | ( Ahmadzad-Asl, M; Amini, M; Davoudi, F; Einollahi, B; Khedmat, H; Lessan-Pezeshki, M; Naseri, MH; Pourfarziani, V, 2007) |
| "For patients with ESRD with uncontrolled hyperparathyroidism who are good candidates for either drug therapy or surgery, cinacalcet hydrochloride is the most cost-effective modality if the patient is to remain on dialysis therapy for 7." | ( Abbott, KC; Berbano, EP; Narayan, R; Neff, RT; Perkins, RM; Sawyers, ES; Vidal-Trecan, GM; Yeo, FE; Yuan, CM, 2007) |
| "Data on 515 561 patients beginning ESRD treatment between January 1, 1996, and June 30, 2004, were obtained for this cross-sectional survey from the United States Renal Data System." | ( Ward, MM, 2007) |
| "In conclusion, patients with ESRD treated with hemodialysis and postrenal transplantation patients, across both genders, were observed to have skeletal disturbances." | ( Grzeszczak, W; Gumprecht, J; Pluskiewicz, W; Zwiec, J; Zywiec, J, 2007) |
| "The 69-year-old man with chronic renal failure due to polycystic renal dysplasia had received hemodialysis treatment for 10 years." | ( Handrick, W; Heine, C; Hugo, F; Seeger, W, 2007) |
| "In patients with chronic renal failure, the administration of folic acid or its metabolites reduces but does not normalize plasma homocysteine concentrations." | ( Alberghini, E; Baragetti, I; Buccianti, G; Buzzi, L; Catapano, AL; Furiani, S; Garlaschelli, K; Raselli, S; Stucchi, A; Terraneo, V, 2007) |
| "We describe a unique case with ESRD and pulmonary embolism who was treated with fondaparinux owing to the toxicity and poor compliance with low-molecular-weight heparin." | ( Crandall, C; Lin, JJ; Pipe, S; Sharathkumar, AA, 2007) |
| "Fifty-two HD patients with chronic renal failure were involved--26 with rHuEPO treatment (EPO group) and 26 without (non-EPO group)." | ( Galajda, P; Hollý, P; Ivanková, J; Kubisz, P; Rozborilová, E; Stasko, J, 2007) |
| "In patients with ESRD, the cardiorespiratory analysis, is valid for the diagnosis and correctly detect the SaO2 at night, both being key parameters for the diagnostic and treatment of SAHS." | ( Aljama, P; Fernández Marín, MC; Jurado Gámez, B; Martín-Malo, A; Muñoz, L, 2008) |
| "Patients with ESRD were prospectively registered in the renal replacement therapy (RRT) database in the nephrology unit." | ( Hooi, LS; Liu, WJ, 2007) |
| "Eighty-three ESRD patients, including 51 who underwent haemodialysis and 32 who underwent peritoneal dialysis therapy, received a quadruple recombinant hepatitis B vaccine." | ( Huang, CC; Kuo, HL; Lin, HH; Lin, PW; Liu, JH; Liu, YL; Yang, YF, 2009) |
| "Fifty-three patients with ESRD were enrolled in this study and were treated by CAPD." | ( Göçmen, AY; Gümüşlü, S; Koçak, H; Sahin, E; Tuncer, M, 2008) |
| "Our data have demonstrated that ESRD patients on CAPD treatment exhibit increased lipid peroxidation reactions and decreased antioxidant protection." | ( Göçmen, AY; Gümüşlü, S; Koçak, H; Sahin, E; Tuncer, M, 2008) |
| "In patients with chronic renal failure, the ability to reduce the administration frequency of subcutaneous (SC) erythropoietin (epoetin) could provide benefits and may improve compliance." | ( Kim, HJ; Kim, SG; Koo, JR; Lee, YK; Noh, JW; Oh, JE; Seo, JW; Yoon, JW, 2008) |
| "The PRL profile in ESRD patients treated with hemodialysis, peritoneal dialysis and in predialysis period is changed." | ( Kulicki, P; Matuszkiewicz-Rowińska, J; Niemczyk, L; Niemczyk, S; Ostrowski, G; Sitkowska-Kurzec, Z; Szamotulska, K; Zalewska-Waśniewska, A, 2006) |
| "Inflammation in an ESRD patient may impact responsiveness to erythropoiesis-stimulating agent (ESA) therapy." | ( Bradbury, BD; Critchlow, CW; Hakim, RH; Krishnan, M; Stewart, R; Weir, MR, 2009) |
| "Correlates of ESRD were older age and higher creatinine at biopsy, the absence of combined IS/RAS blockade therapy and the presence of subepithelial humps, but not histologic pattern." | ( Appel, GB; D'Agati, VD; Markowitz, GS; Nasr, SH; Said, SM; Sherwinter, J; Stokes, MB; Valeri, AM, 2009) |
| "Here, we report a patient with chronic renal failure who developed EPO-resistant anemia after amiodarone treatment for arrhythmia." | ( Chang, PM; Ng, YY, 2008) |
| "Initiation of ESRD treatment was ascertained using US Renal Data System registry data through December 31, 2000." | ( Darbinian, J; Go, AS; Hsu, CY; Iribarren, C; McCulloch, CE, 2009) |
| "Rhubarb is well used to treat chronic renal failure (CRF) in China and Japan, but recent studies reported that the anthraquinone derivatives contained in rhubarb had nephrotoxicity." | ( Jin, C; Li, H; Wang, J; Xiao, X; Zhang, P; Zhao, H; Zhao, Y, 2009) |
| "NSF was not observed in ESRD patients undergoing MRI without administration of GBCA." | ( Geusau, A; Haumer, M; Heinz-Peer, G; Neruda, A; Vychytil, A; Watschinger, B; Weber, M, 2010) |
| "The rat models were randomized into chronic renal failure group, alpha-keto acid group and normal control group, and after a 4-week treatment as indicated, neuropeptide Y mRNA levels in the hypothalamus were measured by RT-PCR in rats with surgically induced renal failure (two-stage subtotal nephrectomy)." | ( Deng, C; Hu, HY; Long, HB; Xiao, W; Zhou, WD, 2009) |
| "pylori eradication are as effective in chronic renal failure patients as in normal population, but the frequency of side effects of amoxicillin is higher in the patients not receiving dialysis therapy." | ( Jee, SR; Kim, JH; Moon, JS; Park, SH; Shin, WG, 2009) |
| "Because chronic renal failure has been associated with oxidative stress, we hypothesize that EPO treatment could accentuate this condition and contribute to hypertension." | ( Agharazii, M; Larivière, R; Lebel, M; Rancourt, ME; Rodrigue, ME, 2010) |
| "Nine lucid, very old > 80 years, ESRD patients who had refused to start dialysis were prescribed a treatment based on a combination of a very low protein diet and oral activated charcoal (30 gram/day)." | ( Algranati, L; Martinez, B; Michelangelo, H; Musso, CG; Parot, M; Quevedo, M; Reynaldi, J; Vidal, F; Waisman, G, 2010) |
| "A 63-year-old man on hemodialysis for chronic renal failure developed a metastatic urothelial carcinoma and was treated with combination chemotherapies." | ( Hirai, T; Ichikawa, Y; Kishikawa, H; Kobayashi, Y; Nishimura, K; Soda, T; Yamanaka, K, 2010) |
| "We report a case of ET and chronic renal failure treated with anagrelide and low-dose aspirin in a patient who did not receive transfusion and surgical intervention due to religious reasons, and had a fatal outcome." | ( Demulder, AC; Malarme, M; Mesquita, Mdo C; Noubouossie, D; Sol, EB, 2009) |
| "Using the RMR model of chronic renal failure (CRF), we assessed the effects of twelve weeks' administration of L-arginine and/or a mixture of antioxidants (L-carnitine, catechin, vitamins E and C) on plasma cytokines, soluble intercellular adhesion molecule-1 (sICAM-1), nitrate and nitrites (NO(2)/NO(3)), lipid profile, blood pressure, and renal function." | ( Korish, AA, 2010) |
| "We report a case of ESRD due to renal limited anti-GBM disease with circulating anti-GBM-ab resistant to standard treatment approach who achieved undetectable anti-GBM-ab with mycophenolic acid." | ( Gok, E; Horoz, M; Kiykim, AA, 2010) |
| "Five patients had chronic renal failure at the beginning of treatment, of whom three and one reached end-stage renal failure within 1 and 3 years, respectively." | ( Di Zazzo, G; Emma, F; Giannakakis, K; Legato, A; Massella, L; Muda, AO, 2010) |
| "As a treatment method for chronic renal failure (CRF), hemodialysis (HD) alters inorganic components containing trace elements." | ( Berber, A; Demir, TA; Koca, HB; Koca, T; Koken, T, 2010) |
| "Treatment of skin from ESRD patients with Omniscan stimulated production of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinases-1, but not type I procollagen." | ( Dame, MK; DaSilva, M; Fligiel, SE; Johnson, KJ; O'Brien Deming, M; Swartz, RD; Varani, J, 2010) |
| "With the incidence of ESRD on the rise, there is a continuing need to control anemia-related treatment costs in dialysis patients receiving reimbursement through Medicare." | ( Charytan, C, 2010) |
| "In this study, we used a rat model of chronic renal failure (CRF) to examine the long-term effects of controlling serum phosphorus with lanthanum carbonate treatment on the biochemical and bone abnormalities associated with CKD-mineral and bone disorder (CKD-MBD)." | ( Damment, S; Lorenzo, V; Rodriguez, M; Secker, R; Shen, V, 2011) |
| "Three patients with ESRD were successfully treated for VTE with unmonitored, fixed-dose subcutaneous UFH every 12 hours and dose-adjusted warfarin." | ( Chesson, MM; Metzger, NL, 2010) |
| "In conclusion, ESRD patients with HCV infection should be encouraged to receive antiviral therapy, and those who achieve an SVR usually have long-term, durable, virological, biochemical, and histological responses." | ( Kao, JH; Liu, CH, 2011) |
| "Oral lesions secondary to chronic renal failure or related to immunosuppressive therapy after transplant are reported in the literature, but their prevalence is still obscure." | ( Alanis, LR; Casagrande, RW; Dantas, SA; de Lima, AA; Dirschnabel, AJ; Grégio, AM; Ignacio, SA; Machado, MÂ; Martins, Ade S; Ribas, Mde O; Trevilatto, PC, 2011) |
| "Thus, in the majority of ESRD patients, PO(4) binders remain the mainstay of therapy for hyperphosphatemia." | ( Molony, DA; Stephens, BW, 2011) |
| "The exact number of patients with chronic renal failure requiring renal replacement therapy in developing world is not known." | ( Dakshinamurty, KV; Prasad, N; Ram, R; Swarnalatha, G, 2011) |
| "Peritonitis frequently occurred in ESRD children treated by CAPD in Northeast Thailand, particularly from gram-positive organisms." | ( Jiravuttipong, A; Lertchanaruengrith, P; Wisanuyotin, S, 2011) |
| "154 end-stage renal disease (ESRD) patients under HD treatment (92 M, 62 F, mean age 53 ± 15 y, mean duration of HD treatment 92 ± 65 months) were enrolled." | ( Karakan, S; Ozdemir, FN; Sezer, S, 2011) |
| "The blood Cr level just reached the chronic renal failure level on the 26th day of the administration (about the 4th week), and obviously exceeded the renal failure level on the 41st day (about the 6th week)." | ( Meng, DM; Ren, W; Xing, RL, 2011) |
| "In a rat model of chronic renal failure, 5/6-nephrectomized [5/6N] rats were treated orally with DPP-4 inhibitors (linagliptin, sitagliptin, alogliptin) or placebo once daily for 4 days from 8 weeks after surgery, to identify the most appropriate treatment for cardiac dysfunction associated with CKD." | ( Alter, M; Chaykovska, L; Fuchs, H; Heiden, S; Hocher, B; Klein, T; Rahnenführer, J; Runge, F; von Websky, K, 2011) |
| "When treating patients with chronic renal failure, physicians should be aware of these rare but potentially severe adverse reactions." | ( Chang, MO; Chang, YS; Chung, S; Kim, MJ; Koh, ES; Park, CW; Shin, SJ, 2012) |
| "In experimental chronic renal failure, elevated levels of MBG contribute to hypertension and induce cardiac fibrosis via suppression of Fli-1, representing a potential target for therapy." | ( Bagrov, AY; Budny, GV; Fedorova, OV; Haller, ST; Kennedy, DJ; Malhotra, D; Shapiro, JI; Shidyak, A, 2012) |
| "Despite treatment, she progressed to ESRD within four and a half years from the time of diagnosis." | ( Brennan, DC; Gaut, JP; Java, A, 2012) |
| "IV iron administration in ESRD patients impairs bacteriocidal capacity of polymorphonuclear leukocytes (PMNs) against Escherichia coli." | ( Gollapudi, S; Hassanzadeh, T; Ichii, H; Masuda, Y; Saffarian, M; Vaziri, ND, 2012) |
| "RTx is best treatment for children with ESRD." | ( Gera, DN; Gumber, MR; Kute, VB; Modi, PR; Munjappa, BC; Patel, HV; Shah, PR; Trivedi, HL; Vanikar, AV, 2012) |
| "The study included 24 chronic renal failure (CRF) patients on HD treated with rHuEPO as well as 14 normal control subjects." | ( Abdalla, M; Darwish, KH; Yassein, S, 2010) |
| "The DEcIDE Patient Outcomes in ESRD Study will provide needed evidence regarding the effectiveness of common treatments employed for dialysis patients." | ( Bandeen-Roche, K; Boulware, LE; Crews, DC; Ephraim, PL; Jaar, BG; Liu, J; Miskulin, DC; Navaneethan, SD; Powe, NR; Scialla, JJ; Shafi, T; Sozio, SM; St Peter, W; Tangri, N; Wu, AW, 2012) |
| "In our ESRD cohort, the percentage of INR in target range in patients treated with phenprocoumon seems comparable with published data on warfarin and data in non-ESRD populations." | ( Grandjean, R; Mayr, M; Praehauser, C; Steiger, J, 2013) |
| "Therapy for a 78-year-old man with ESRD who required peritoneal dialysis was started with leflunomide 10 mg/day for psoriatic arthritis." | ( Ahern, MJ; Barbara, JA; Russo, PA; Shanahan, EM; Smith, MD; Wiese, MD, 2013) |
| "After 1 week, rats with chronic renal failure were treated with vehicle, 375 or 750 mg/kg CaMg, or 750 mg/kg sevelamer by daily gavage for 5 weeks." | ( Behets, GJ; D'Haese, PC; De Schutter, TM; Geryl, H; Gundlach, K; Neven, E; Passlick-Deetjen, J; Peter, ME; Steppan, S, 2013) |
| "He had been treated for chronic renal failure." | ( Endo, S; Fujino, Y; Fujita, Y; Inoue, Y; Kikuchi, S; Onodera, M; Shozushima, T, 2013) |
| "In conclusion, ESRD surgical patients undergoing PD treatment appear to have significantly higher baseline cerebral tissue saturation values compared with HD." | ( Dounousi, E; Papadopoulos, G; Papathanakos, G; Papathanasiou, A; Tzimas, P, 2013) |
| "The patient had chronic renal failure and was on regular hemodialysis treatment for 12 years." | ( Eom, Y; Han, JY; Huh, K; Kang, SY; Kim, HM; Song, JS, 2013) |
| "The primary end point was ESRD requiring renal replacement therapy (RRT) or renal transplantation or death." | ( de Joode, AA; Sanders, JS; Stegeman, CA, 2013) |
| "When administering fenofibrate in chronic renal failure, dose should be adjusted." | ( Begenik, H; Canbaz, ET; Emre, H; Erdur, MF; Erkoc, R; Soyoral, YU, 2012) |
| "We report a severe nonresolving chronic renal failure after protracted Dobrava hantavirus infection successfully treated with corticosteroids." | ( Ferluga, D; Kovač, D; Lindič, J; Martinuč Bergoč, M; Pajek, J, 2013) |
| "Sixty-three patients with chronic renal failure due to chronic glomerulonephritis, after receiving a 2-week-long conventional treatment, were randomly divided into alprostadil group (n=20, with alprostadil injection at 10 µg/d for 2 weeks), sequential treatment group (n=21, with alprostadil injection at 10 µg/d for 2 weeks and oral beraprost sodium at 20 µg three times a day for 12 weeks), and strengthened sequential treatment group (n=22, with alprostadil injection at 20 µg/d for 2 weeks and a double dose of oral beraprost sodium for 12 weeks)." | ( Chen, Y; Cui, J; Fu, BB; Jiang, DW; Li, GF; Wan, JX, 2013) |
| "One hundred ESRD patients who were medically stable and under dialysis treatment for at least 6 months were enrolled to the study." | ( Bal, Z; Demirci, BG; Erdoğan, E; Sayın, B; Sezer, S; Tutal, E; Uyar, ME, 2013) |
| "End-stage renal disease (ESRD) and its treatment modules affect almost all organs and organ systems including vascular endothelium." | ( Dragić, S; Kovačević, P; Kovačević, T; Rajkovača, Z; Veljković, S, 2014) |
| "Patients with ESRD and renal osteodystrophy may be successfully surgically and prosthetically treated with long wide dental implants supporting fixed full arch splinted dental prostheses with an appropriate occlusal scheme." | ( Flanagan, D; Mancini, M, 2015) |
| "Patients with chronic kidney failure treated by hemodialysis, hemodiafiltration, hemofiltration, or biofiltration." | ( Covic, A; Craig, JC; Nistor, I; Palmer, SC; Saglimbene, V; Strippoli, GF; Vecchio, M, 2014) |
| "We found 30 ESRD patients with a history of lithium treatment." | ( Aiff, H; Attman, PO; Aurell, M; Bendz, H; Schön, S; Svedlund, J, 2014) |
| "Seventy-five patients (M/F = 40/35) with chronic renal failure (CRF) and who were on HD were divided into five groups with differing treatment periods of HD; from 6 to 24 months to 97-120 months." | ( Demir, S; Karabag, F; Koken, T; Yaman, A, 2014) |
| "Converting patients with ESRD and hyperphosphatemia from SH/C to LC monotherapy offers potential drug cost savings and a significant reduction in the daily tablet burden, without compromising the effective management of serum phosphate levels." | ( Brunelli, SM; Copley, JB; Keith, MS; Sibbel, S; Wilson, RJ, 2014) |
| "53 patients with chronic renal failure receiving hemodialysis treatment and 34 healthy persons were participated to the study." | ( Akyurek, F; Erdem, SS; Kiyici, A; Ozturk, B; Sivrikaya, A; Ugurcu, V; Unlu, A; Vatansev, H, 2014) |
| "Ten non-diabetic HD-treated ESRD patients were included to undergo a 3-h standardized liquid mixed meal test 1 h into an HD and an HDF, respectively." | ( Feldt-Rasmussen, B; Holst, JJ; Hornum, M; Idorn, T; Jørgensen, MB; Knop, FK, 2015) |
| "Incident ESRD defined as initiation of dialysis therapy, transplantation, or death due to kidney disease." | ( Ballantyne, CM; Coresh, J; Grams, ME; Hoogeveen, RC; Kim, Y; Matsushita, K; Sang, Y; Shah, AM; Skali, H; Solomon, SD, 2015) |
| "As most patients progress to ESRD, need for renal replacement therapy, as either dialysis or kidney transplant, usually ensues." | ( Luciano, RL; Perazella, MA, 2015) |
| "Alkali therapy in chronic renal failure (CRF) may ameliorate the progression of kidney disease; however, few studies have examined the effects of alkali therapy on salt sensitivity and kidney injury in CRF." | ( Han, JS; Heo, NJ; Jung, ES; Kim, S; Lee, J; Lee, JW; Na, KY; Yang, JY, 2014) |
| "Rats that had normal kidney function or chronic renal failure that was induced by mass reduction surgery were treated with tacrolimus without or with fish oil, fish oil alone, or olive oil." | ( Abbud-Filho, M; Baptista, MA; Caldas, HC; Fernandes, IM; Fernandes, MB; Toloni, LD, 2014) |
| "Serum PCT levels were measured in ESRD patients on antibiotic therapy for a suspected bacterial infection (ESRD infection [iESRD] group, n = 21), and compared with those of ESRD patients on hemodialysis with no sign of infection (ESRD control [cESRD] group, n = 20)." | ( Back, JH; Chung, JH; Kang, DW; Kim, HL; Lee, WS; Shin, BC, 2015) |
| "USRDS-identified ESRD; treated or untreated kidney failure defined by USRDS-identified ESRD or International Classification of Diseases, Ninth or Tenth Revision, Clinical Modification (ICD-9-CM/ICD-10-CM) code for hospitalization or death." | ( Ballew, SH; Coresh, J; Grams, ME; McMahon, B; Rebholz, CM; Selvin, E; Whelton, SP, 2015) |
| "In terms of the risks of developing ESRD, pentoxifylline alone exerted a comparable beneficial effect to combined therapy with an RAAS inhibitor and greater renoprotection than RAAS inhibitor monotherapy." | ( Chen, CY; Chen, L; Chen, YM; Huang, TM; Lin, CJ; Lin, SL; Pan, CF; Wu, CH; Wu, CJ; Wu, PC; Wu, VC, 2015) |
| "End-stage renal disease (ESRD) patients receiving hemodialysis (HD) are at heightened risk for influenza, but the optimal oseltamivir dosage regimen for treating or preventing influenza in this high-risk population is still uncertain." | ( Clinch, B; Gibiansky, L; Kamal, MA; Lien, KY; Rayner, CR; Robson, R; Subramoney, V, 2015) |
| "End-stage renal disease (ESRD) was defined as the need for renal replacement therapy." | ( Abujam, B; Agarwal, V; Aggarwal, A; Lawrence, A; Misra, R; Srivastava, P, 2016) |
| "Male Wistar rats with chronic renal failure (CRF) induced by 5/6 nephrectomy were treated with rHuEPO or with vehicle, over a 3-week period." | ( Belo, L; Costa, E; Fernandes, J; Garrido, P; Reis, F; Ribeiro, S; Rocha-Pereira, P; Santos-Silva, A; Vala, H, 2016) |
| "In 8 subjects with ESRD, a 15-mg dose of rivaroxaban was administered 2 ± 0." | ( Ariyawansa, J; Dias, C; Mills, RM; Moore, KT; Murphy, J; Smith, W; Weir, MR, 2016) |
| "In this study, we established a chronic renal failure (CRF) model in rats induced by adenine administration prior to Mg implantation, aiming to predict if CRF patients are suitable for the use of Mg implants." | ( Li, Y; Liu, W; Qin, L; Wang, J; Xu, J, 2016) |
| "Three patients with ESRD, two elderly women and one man, underwent dialysis and were treated with LC for 3-36 months." | ( Harada, H; Haratake, J; Hisaoka, M; Matsuyama, A; Shiba, E; Uchihashi, K; Yabuki, K, 2016) |
| "4-PA elimination from the blood of ESRD patients can be potentially followed using monitoring of the fluorescence of the spent dialysate during dialysis treatments." | ( Arund, J; Fridolin, I; Kalle, S; Luman, M; Tanner, R; Tomson, R, 2016) |
| "At present, the main therapy for chronic renal failure (CRF) is dialysis and renal transplantation, but neither obtains satisfactory results." | ( Bian, Y; Chu, X; Cui, H; Li, W; Wang, L, 2017) |
| "Twenty patients with ESRD were treated with Qutenza® for neuropathic pain from critical limb ischemia." | ( Aitken, E; Kingsmore, D; McColl, G, 2017) |
| "Patients with end-stage renal disease (ESRD) have poor treatment tolerance and outcome to interferon-based regimens." | ( Bansal, SB; Bodh, V; Choudhary, NS; Jain, M; Kumar, A; Saigal, S; Saraf, N; Sharma, R, 2017) |
| "Sixteen consecutive patients of ESRD (on dialysis) and chronic hepatitis C were treated with sofosbuvir-based regimens as they were prospective kidney transplantation recipients, at a tertiary care center in north India." | ( Bansal, SB; Bodh, V; Choudhary, NS; Jain, M; Kumar, A; Saigal, S; Saraf, N; Sharma, R, 2017) |
| "Patients with ESRD undergoing chronic hemodialysis and receiving anticoagulation therapy with either apixaban or warfarin were included in this study." | ( Moye, R; Nesbit, R; Sarratt, SC, 2017) |
| "All the newly confirmed ESRD patients who were initiated on renal replacement therapy (RRT) from 1 January to 31 December 2014 were included." | ( Chan, FS; Goh, KW; Lojikip, S; Pang, HC; Wong, KW, 2017) |
| "In patients with chronic renal failure, the addition of CPM-Rheum to ACEI/ARB significantly lowered both SCr and BUN, particularly after long-term administration." | ( Dai, PL; Li, P; Li, WG; Ma, YP; Yang, Y; Zhang, Z, 2018) |
| "Older ESRD patients with AF who were treated with warfarin had a no difference in stroke risk, lower mortality risk, but increased major bleeding risk." | ( Alexander, GC; Bae, S; McAdams-DeMarco, M; Segal, JB; Segev, DL; Tan, J; Zhu, J, 2019) |
| "Patients with end-stage renal disease (ESRD) requiring intermittent haemodialysis (IHD) are at high risk of MRSA bacteraemia (MRSA-B) and often fail first-line therapy." | ( Britt, NS; Casabar, E; McManus, D; Nizet, V; Ritchie, DJ; Sakoulas, G; Tirmizi, S; Topal, JE, 2018) |
| "Patients with ESRD undergo frequent maintenance (haemo)dialysis treatment, and finally must receive a combined liver-kidney transplantation as the only curative treatment option available in PH Type 1." | ( Hoppe, B; Kurts, C; Ludwig-Portugall, I; Martin-Higueras, C, 2019) |
| "Twenty patients with ESRD on dialysis with calciphylaxis who were treated with apixaban for indications of deep vein thrombosis or atrial fibrillation were identified." | ( Garza-Mayers, AC; Kroshinsky, D; Nigwekar, SU; Shah, R; Sykes, DB, 2018) |
| "We studied patients with ESRD who underwent arteriovenous fistula surgery and received peroral administration of 40 µg BPS, three times per day, for 1 month, or 75 mg CL (initial dose of 300 mg), one time per day, for 1 month." | ( Cao, L; Gui, K; Li, N; Wan, Z; Wang, Q; Xiong, M; Yan, W; Yang, C; Yang, R; Zhang, Y; Zhao, M; Zhu, Y, 2019) |
| "CL-treated patients with ESRD have a greater risk of VTEs compared with BPS-treated patients." | ( Cao, L; Gui, K; Li, N; Wan, Z; Wang, Q; Xiong, M; Yan, W; Yang, C; Yang, R; Zhang, Y; Zhao, M; Zhu, Y, 2019) |
| "The study group enrolled 62 ESRD patients treated with hemodialysis three times weekly." | ( Kamperidis, V; Kapoukranidou, D; Karvounis, H; Konstantinou, D; Spartalis, E; Spartalis, M; Tzatzaki, E, 2018) |
| "From Jan 2009 to May 2015, 346 ESRD cases suffering an AVF surgery and undergoing oral administration of 75 mg CL (initial dose of 300 mg), 1 time/day, for 4 weeks or 40 μg BPS, 3 times/day, for 4 weeks were retrospectively assessed." | ( Du, L; Du, X; Lai, J; Lai, Q; Tu, B; Wan, Z; Xu, B; Zhang, F; Zhao, M; Zhou, Y, 2018) |
| "SH treatment of patients with ESRD is more effective compared to LC treatment." | ( Li, H; Lin, Z; Xie, W; Zhou, T, 2018) |
| "Rat models of chronic renal failure and hyperphosphatemia were induced by adenine, which were treated with nano-LH (0." | ( Li, G; Liu, D; Ma, Z; Miao, X; Wu, Y; Xing, H; Yu, T; Zhang, X, 2019) |
| "End-stage renal disease (ESRD) is increasing globally, and renal transplantation (RT) is the preferred renal replacement therapy to treat ESRD." | ( Gan Kim Soon, P; Lim, SK; Rampal, S; Su, TT, 2019) |
| "Animal models of chronic kidney failure (CKF) have been developed for the pharmacodynamic evaluation of various phosphate binders that are used clinically to treat hyperphosphatemia in patients with chronic kidney disease." | ( Kano, M; Katoh, M; Okabe, T; Okazaki, R; Tanaka, Y; Toyoda, H; Ueno, M, 2019) |
| "Clinicians caring for patients with ESRD should have a low threshold for objective sleep assessment given that sleep disorders are common, disabling and eminently amenable to treatment." | ( Conlon, P; Costello, R; Kane, T; Kennedy, C, 2019) |
| "Perspiration therapy for ESRD experienced a surge in the United States in the 1960s but does not have much modern momentum." | ( Kalantar-Zadeh, K; Keller, RW; Kopple, JD, 2020) |
| "We detail six cases of ESRD-associated hypoglycemia which responded to treatment with diazoxide therapy." | ( Kristan, M; Lamos, EM; Malek, R; Mesmar, B; Munir, KM; Satyarengga, M, 2020) |
| "End-stage renal disease (ESRD) related to HIV is becoming a leading cause of renal replacement therapy requirement is some areas of the world." | ( Contreras-Villamizar, K; Garcia-Consuegra, E; García-Peña, Á; Garzón-Herazo, J; Muñoz-Velandia, O; Rodríguez-Sánchez, M; Toro-Trujillo, E, 2020) |
| "SLE manifestations after ESRD may be underdiagnosed and undertreated, contributing to increased morbidity and mortality." | ( Broder, A; Dobrowolski, C; Goilav, B; Londono Jimenez, A; Mowrey, WB; Salgado Guerrero, M; Wang, S, 2020) |
| "Patients with AMI with ESRD on statin therapy exhibited a significantly lower risk of mortality compared with non-statin users (p<0." | ( Cheng, CC; Cheng, JT; Chiang, CH; Chuang, TJ; Huang, WC; Kuo, FY; Lin, HC; Liu, CP; Mar, GY; Tang, PL; Wann, SR; Wu, MC, 2021) |
| "Among patients with ESRD with AMI, statin therapy was associated with reduced all-cause mortality." | ( Cheng, CC; Cheng, JT; Chiang, CH; Chuang, TJ; Huang, WC; Kuo, FY; Lin, HC; Liu, CP; Mar, GY; Tang, PL; Wann, SR; Wu, MC, 2021) |
| "Male sex, ESRD, MMF use, intravenous steroid pulse therapy, and oral prednisolone or equivalent treatment (>7." | ( Chang, YS; Chen, WS; Huang, YF; Lai, CC; Li, TH; Tsao, YP; Wang, WH, 2022) |
| "Hereby, ESRD patients can be treated without general anesthesia, while ensuring functionality of the PD catheter." | ( Fütterer, C; Jabbour, E; Kälsch, AI; Keese, M; Krämer, BK; Rahbari, NN; Schwenke, KG; Zach, S, 2021) |
| "Eighteen ESRD patients undergoing hemodialysis were evaluated by blood sample, MVRC, and frequency ramp (before and near the end of dialysis treatment), quantitative electromyography, and nerve conduction studies." | ( Bostock, H; Buus, NH; Larsen, LH; Tan, SV; Tankisi, H; Z'Graggen, WJ, 2021) |
| "Patients with end-stage renal disease (ESRD) have high rates of cardiac valvulopathy but can develop contraindications for vitamin K antagonist (VKA) therapy." | ( Holden, RM; Monteith, B; Pilkey, NG; Thomson, BKA, 2021) |
| "The study population was patients with ESRD who were on VKA therapy and developed a contraindication to VKA therapy use." | ( Holden, RM; Monteith, B; Pilkey, NG; Thomson, BKA, 2021) |
| "In patients with ESRD who develop a contraindication to VKA therapy, several alternative anticoagulation strategies have been reported with superior outcomes to VKA continuation." | ( Holden, RM; Monteith, B; Pilkey, NG; Thomson, BKA, 2021) |
| "Of 189 433 older ESRD adults, 92% had a claims diagnosis code of SHPT and 123 388 (65%) were treated for SHPT." | ( Ahn, JB; Chu, NM; Gross, AL; Mathur, A; McAdams-DeMarco, M; Segev, DL; Sutton, W, 2022) |
| "Progression to end-stage renal disease (ESRD) and death was treated as endpoint events." | ( Feng, J; Jin, Y; Li, H; Li, X; Liao, Z; Luo, L; Tang, J; Wang, F; Zhou, F, 2022) |
| "The cohort study included 203 ESRD patients with secondary hyperparathyroidism (SHPT) who received HD treatment." | ( Dudar, I; Dudar, S; Kulish, V; Shifris, I, 2022) |
| "The anemia rate of ESRD patients treated with MHD in Liaoning Province is high." | ( Du, Y; Guo, G; Guo, Y; Sun, D; Yao, L; Yin, S, 2022) |
| "Patients with end-stage renal disease (ESRD) especially those undergoing dialysis have a high prevalence of hyperkalemia, which must be detected and treated immediately." | ( Cui, L; Guan, C; Li, C; Li, H; Li, L; Liu, H; Liu, Y; Xu, D; Xu, L; Xu, Y; Zhang, J; Zhen, L; Zhou, B, 2023) |